"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 4163205 A,063-665-393-378-68X,1979-07-31,1979,US 87240178 A,1978-01-26,US 87240178 A,1978-01-26,Acousto-optical device for removing bubble pulse from reflected sonar signal,"Processing of electrical signals representative of incident and reflected acoustic signals generated by underwater explosion and comprising primary and secondary impulse, or bubble pulse, peaks. Acousto-optic diffraction and optical Fourier transform of the primary or explosive incident signal is performed and photographically recorded to provide a bubble pulse spatial filter. The filter is used in performing subsequent acousto-optic diffraction and optical Fourier transforms to derive impulse response, bottom loss, and an output electrical signal representative of the reflected signal, without the bubble pulse.",BARROW DANIEL,BARROW DANIEL,,https://lens.org/063-665-393-378-68X,Granted Patent,yes,4,7,1,1,0,G01V1/375;;G01V1/375,G01V1/37,340007000R,2,0,,,"Jackson, ""Diffractive Processing of Geophysical Data"", pp. 419-427, Applied Optics, vol. 4, #4, 4/65.;;Maker et al., ""Large Time Bandwidth . . .Matched Filter"", 6/74, pp. 1342-1344, Applied Optics, vol. 13, #6.",EXPIRED
2,WO,A1,WO 2022/235529 A1,174-713-660-509-209,2022-11-10,2022,US 2022/0027179 W,2022-05-01,US 202163183579 P,2021-05-03,METHOD OF TITRATING DOSE OF PSYCHEDELICS,"A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/174-713-660-509-209,Patent Application,yes,2,0,5,5,0,A61K31/4045;;A61P25/00;;A61K31/48;;A61K31/675;;A61K31/137;;A61P25/00;;A61K31/4045;;A61K31/675;;A61K31/137;;A61K31/48,A61P25/00;;A61K31/4045;;A61K31/407;;A61K31/437,,4,3,114-133-862-046-890;;015-894-264-081-896;;026-008-329-607-925,31778967;;10.1016/j.drugpo.2019.11.008;;10.1007/s00213-018-5119-x;;pmc6591199;;30478716;;33082016;;10.1016/j.euroneuro.2020.10.002,"LEA TOBY; AMADA NICOLE; JUNGABERLE HENRIK; SCHECKE HENRIKE; KLEIN MICHAEL: ""Microdosing psychedelics: Motivations, subjective effects and harm reduction"", INTERNATIONAL JOURNAL OF DRUG POLICY, vol. 75, 25 November 2019 (2019-11-25), AMSTERDAM, NL , XP085977092, ISSN: 0955-3959, DOI: 10.1016/j.drugpo.2019.11.008;;YANAKIEVA ET AL.: ""The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial"", PSYCHOPHARMACOLOGY, vol. 236, 26 November 2018 (2018-11-26), pages 1159 - 1170, XP037275698, DOI: 10.1007/s00213-018-5119-x;;BERSHAD ANYA K.; SCHEPERS SCOTT T.; BREMMER MICHAEL P.; LEE ROYCE; DE WIT HARRIET: ""Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers"", BIOLOGICAL PSYCHIATRY, vol. 86, no. 10, 3 June 2019 (2019-06-03), AMSTERDAM, NL, pages 792 - 800, XP085872159, ISSN: 0006-3223, DOI: 10.1016/j.biopsych.2019.05.019;;HUTTEN NADIA R.P.W.; MASON NATASHA L.; DOLDER PATRICK C.; THEUNISSEN EEF L.; HOLZE FRIEDERIKE; LIECHTI MATTHIAS E.; FEILDING AMAND: ""Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study"", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 41, 17 October 2020 (2020-10-17), NL , pages 81 - 91, XP086384649, ISSN: 0924-977X, DOI: 10.1016/j.euroneuro.2020.10.002",PENDING
3,US,A1,US 2023/0346645 A1,039-885-064-490-659,2023-11-02,2023,US 202217734098 A,2022-05-01,US 202217734098 A,2022-05-01,METHOD OF TITRATING DOSE OF PSYCHEDELICS,"A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment.",BARROW ROBERT;;KARLIN DANIEL R;;MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,MIND MEDICINE INC (2021-05-12),https://lens.org/039-885-064-490-659,Patent Application,yes,0,0,1,1,0,A61K31/48;;A61K31/675;;A61K31/137;;A61K31/4045;;A61J7/0069;;A61J7/0076;;A61J1/035;;A61K45/06;;A61J7/04;;G16H20/10,A61J1/03;;A61J7/00;;A61J7/04;;A61K45/06;;G16H20/10,,0,0,,,,PENDING
4,TW,A,TW 202245765 A,168-369-985-541-736,2022-12-01,2022,TW 111116663 A,2022-05-03,US 202163183771 P,2021-05-04,Movement disorders,"A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/168-369-985-541-736,Patent of Addition,no,0,0,3,4,0,A61P25/14;;A61K31/437;;A61K31/4045;;A61K31/137;;A61K31/36;;A61K31/48;;A61K31/675;;A61K31/437;;A61P25/14;;A61K45/06;;A61K31/4045,A61K31/48;;A61P25/14,,0,0,,,,PENDING
5,GB,B,GB 2482313 B,102-079-582-565-100,2012-12-05,2012,GB 201012664 A,2010-07-28,GB 201012664 A,2010-07-28,Structures of substantially rigid and foldable material,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;BARROW LASCELLE AUGUSTUS,,https://lens.org/102-079-582-565-100,Granted Patent,no,5,0,3,3,0,G09F1/06;;G09F1/065;;G09F15/0025;;G09F15/0062;;G09F15/0062;;G09F1/06;;G09F1/065,G09F1/06;;G09F15/00,,0,0,,,,INACTIVE
6,WO,A9,WO 2022/265878 A9,016-397-797-206-400,2023-07-27,2023,US 2022/0032401 W,2022-06-06,US 202163210346 P,2021-06-14,CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION,"A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminating its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug. A method of stopping psychosis due to psychedelic administration, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug, and stopping psychosis caused by the psychedelic drug.",MIND MEDICINE INC,KARLIN DANIEL R;;BARROW ROBERT,,https://lens.org/016-397-797-206-400,Search Report,yes,0,0,3,3,0,A61K31/48;;A61P25/00;;A61P25/00;;A61K31/48,A61K31/48;;A61K31/17;;A61K31/4465;;A61K45/00,,0,0,,,,PENDING
7,WO,A1,WO 2022/235500 A1,042-064-092-526-655,2022-11-10,2022,US 2022/0026921 W,2022-04-29,US 202163183578 P,2021-05-03,PSYCHEDELICS FOR TREATMENT OF PAIN,"A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/042-064-092-526-655,Patent Application,yes,4,0,3,4,0,A61K31/4045;;A61K31/48;;A61K31/137;;A61K31/675;;A61P25/04;;A61K31/675;;A61K31/48;;A61P25/04;;A61K31/137;;A61K31/4045,A61K31/4045;;A61K31/675;;A61K45/06,,0,0,,,,PENDING
8,GB,A,GB 2482313 A,053-459-284-734-251,2012-02-01,2012,GB 201012664 A,2010-07-28,GB 201012664 A,2010-07-28,Self-expanding convex display stand,"A foldable, self-expanding convex display stand 10, e.g. of card or cardboard comprises a tubular sleeve 40 composed of two panels 11, 12 that have a bowed form. Biasing means 15 are provided to bias the panels into the expanded, bowed configuration, comprising a polygonal prism sub structure with mutually hinged walls permitting the sub-structure to be compacted to a substantially flat condition, and an elastic band (30, Fig. 4) to urge the substructure into an expanded condition. The sleeve may be divided into a number of sections by fold lines 45 which may be folded with respect to one another in zig-zag fashion when in the collapsed configuration to provide a compact form, e.g. for storage in a container (48, Fig. 1).",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;BARROW LASCELLE AUGUSTUS,,https://lens.org/053-459-284-734-251,Patent Application,no,5,3,3,3,0,G09F1/06;;G09F1/065;;G09F15/0025;;G09F15/0062;;G09F15/0062;;G09F1/06;;G09F1/065,G09F1/06;;G09F15/00,,0,0,,,,INACTIVE
9,CN,A,CN 117295710 A,130-527-642-625-198,2023-12-26,2023,CN 202280032466 A,2022-05-01,US 202163184703 P;;US 2022/0027180 W,2021-05-05,MDMA enantiomers,"A composition of the R (-) enantiomer of MDMA or MDA for use in psychotherapy or medical treatment is disclosed. A method of treating a medical condition in a subject, particularly autism and social anxiety disorders, by administering an effective amount of a composition of R (-) enantiomers of MDMA or MDA, and treating the subject. A method of reducing neurotoxicity of MDMA and MDA by administering to a subject an effective amount of a composition of R (-) enantiomers of MDMA or MDA, and reducing neurotoxicity of MDMA or MDA when treating the subject. A method of reducing hyperthermia of MDMA and MDA. A method of reducing the propensity of somatic dependence or abuse of MDMA and MDA.",3V MEDICAL INC,BARROW ROBERT;;CARLIN DANIEL R,,https://lens.org/130-527-642-625-198,Patent Application,no,0,0,7,10,0,A61K31/36;;A61P25/28;;A61K31/36;;A61K45/06;;A61P25/28;;A61K31/36;;A61P25/28;;A61K45/06,C07C231/02,,0,0,,,,PENDING
10,TW,A,TW 202245766 A,162-978-195-670-141,2022-12-01,2022,TW 111116664 A,2022-05-03,US 202163183578 P,2021-05-03,Psychedelics for treatment of pain,"A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/162-978-195-670-141,Patent of Addition,no,0,0,3,4,0,A61K31/4045;;A61K31/48;;A61K31/137;;A61K31/675;;A61P25/04;;A61K31/675;;A61K31/48;;A61P25/04;;A61K31/137;;A61K31/4045,A61K31/48;;A61P25/04;;A61P29/00,,0,0,,,,PENDING
11,WO,A1,WO 2022/235531 A1,170-990-196-684-985,2022-11-10,2022,US 2022/0027181 W,2022-05-01,US 202163183771 P,2021-05-04,MOVEMENT DISORDERS,"A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/170-990-196-684-985,Patent Application,yes,5,0,3,4,0,A61P25/14;;A61K31/437;;A61K31/4045;;A61K31/137;;A61K31/36;;A61K31/48;;A61K31/675;;A61K31/437;;A61P25/14;;A61K45/06;;A61K31/4045,A61P25/14;;A61K31/4045;;A61K31/407;;A61K31/437,,3,3,094-772-484-544-514;;013-476-234-746-274;;102-305-370-078-004,18344392;;10.1136/jnnp.2007.131045;;10.1177/1756285613495723;;24409202;;pmc3886380;;10.1007/bf02955387,"J JANKOVIC: ""Parkinson's disease: clinical features and diagnosis"", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY., BMJ PUBLISHING GROUP, GB, vol. 79, no. 4, 14 March 2008 (2008-03-14), GB , pages 368 - 376, XP055628764, ISSN: 0022-3050, DOI: 10.1136/jnnp.2007.131045;;CHEN JACK J., MARSH LAURA: ""Anxiety in Parkinson’s disease: identification and management"", THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS MAY 2010, vol. 7, no. 1, 1 January 2014 (2014-01-01), pages 52 - 59, XP093006487, ISSN: 1756-2864, DOI: 10.1177/1756285613495723;;CHARLES G. SMITH M.B., M.R.C.P.I., D.P.M.: ""GILLES DE LA TOURETTE SYNDROME TREATED WITH LSD"", IRISH JOURNAL OF MEDICAL SCIENCE, vol. 2, no. 6, June 1969 (1969-06-01), IE , pages 269 - 271, XP009541176, ISSN: 0021-1265",PENDING
12,TW,A,TW 202245767 A,017-070-203-480-157,2022-12-01,2022,TW 111116665 A,2022-05-03,US 202163183579 P,2021-05-03,Method of titrating dose of psychedelics,"A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/017-070-203-480-157,Patent of Addition,no,0,0,5,5,0,A61K31/4045;;A61P25/00;;A61K31/48;;A61K31/675;;A61K31/137;;A61P25/00;;A61K31/4045;;A61K31/675;;A61K31/137;;A61K31/48,A61K31/48;;A61P25/00,,0,0,,,,PENDING
13,US,A1,US 2022/0347195 A1,066-402-792-315-824,2022-11-03,2022,US 202217732878 A,2022-04-29,US 202217732878 A;;US 202163183578 P,2021-05-03,PSYCHEDELICS FOR TREATMENT OF PAIN,"A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,MIND MEDICINE INC (2021-05-12),https://lens.org/066-402-792-315-824,Patent Application,yes,2,0,3,4,0,A61K31/4045;;A61K31/48;;A61K31/137;;A61K31/675;;A61P25/04;;A61K31/675;;A61K31/48;;A61P25/04;;A61K31/137;;A61K31/4045,A61K31/675;;A61K31/137;;A61K31/4045;;A61K31/48;;A61P25/04,,3,2,073-260-272-551-236;;039-835-379-707-626,10.1093/bjaceaccp/mkq054;;14169837;;10.1213/00000539-196405000-00013,"Cortés-Cartagena, M.. Designing an LSD micro-dose transdermal patch for mental illness drug therapy, Design Project Article for the Graduate Programs at Polytechnic University of Puerto Rico, issued 2020, available 2021-01-27, http://hdl.handle.net/20.500.12475/1077 (Year: 2020);;Sanjay Bajaj, Abigail Whiteman, Brigitta Brandner, Transdermal drug delivery in pain management, Continuing Education in Anaesthesia Critical Care & Pain, Volume 11, Issue 2, Pages 39–43, https://doi.org/10.1093/bjaceaccp/mkq054 (Year: 2011);;ERIC C. KAST, VINCENT J. COLLINS, Lysergic Acid Diethylamide as an Analgesic Agent, Anesthesia and Analgesia, Current Research, Vol 43, 3, (Year: 1964)",PENDING
14,US,A1,US 2022/0354822 A1,077-450-834-045-398,2022-11-10,2022,US 202217734100 A,2022-05-01,US 202217734100 A;;US 202163184703 P,2021-05-05,MDMA ENANTIOMERS,"A composition for use in psychotherapeutic or medical treatment of an R(−) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,MIND MEDICINE INC (2021-05-13),https://lens.org/077-450-834-045-398,Patent Application,yes,0,3,7,10,0,A61K31/36;;A61P25/28;;A61K31/36;;A61K45/06;;A61P25/28;;A61K31/36;;A61P25/28;;A61K45/06,A61K31/36;;A61K45/06;;A61P25/28,,13,9,076-506-896-151-659;;006-464-225-711-158;;014-697-709-573-502;;001-823-496-675-128;;011-433-585-516-187;;025-143-594-826-278;;124-740-925-596-601;;024-582-172-375-866;;024-867-531-705-978,10.1007/s00213-017-4812-5;;29248945;;10.1177/0269881110378371;;pmc3122379;;20643699;;31943218;;10.1111/1556-4029.14268;;21539403;;10.2165/11588190-000000000-00000;;18644153;;10.1186/1472-6904-8-4;;pmc2496900;;17564678;;10.1111/j.1471-4159.2007.04451.x;;10.1016/s0091-3057(01)00770-5;;11900801;;28993129;;10.1016/j.neuropharm.2017.10.003;;pmc5714650;;pmc6703214;;21562283;;10.1523/jneurosci.1171-11.2011,"Pitts et al. ""(+-)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA"" Psychopharmacology. 235:377-392 (Year: 2018);;Mithoefer et al. ""The safety and efficacy of +-3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study"" J Psychopharmacol. 25(4):439-452 (Year: 2011);;Elliott et al. ""Prodrugs of New Psychoactive Substances (NPS): A New Challenge"" J Forensic Sci. 65(3):913-920 (Year: 2020);;Ermer et al. ""Intranasal versus Oral Administration of Lisdexamfetamine Dimesylate"" Clin Drug Investig. 31(6):357-370 (Year: 2011);;Mendelson et al. ""The Clinical Pharmacology of Intranasal l-Methamphetamine"" BMC Clinical Pharmacology. 8:4 (Year: 2008);;ACQUAS ET AL. Journal of Neurochemistry, 2007, vol. 102, p.121-132 (Year: 2007);;GLENNON ET AL. Pharmacology, Biochemistry and Behavior, 2002, vol. 72, p.307-311 (Year: 2002);;WANG ET AL. Psychopharmacology, 2007, vol. 189, p.483-488 (Year: 2007);;FRAU ET AL. Journal of Neurochemistry, 2013, vol. 124, p.69-78 (Year: 2013);;CURRY ET AL. Neuropharmacology, 2018, vol. 128, p.196-206 (Year: 2018);;OEHEN ET AL. Journal of Psychopharmacology, 2013, vol. 27, no. 1, p.40-52 (Year: 2013);;LYON ET AL. Psychopharmacology, 1986, vol. 88, p.525-526 (Year: 1986);;HUOT ET AL. The Journal of Neuroscience, 2011, vol. 31, no. 19, p.7190-7198 (Year: 2011)",PENDING
15,IL,A,IL 308068 A,175-633-970-628-63X,2023-12-01,2023,IL 30806823 A,2023-10-26,US 202163183579 P;;US 2022/0027179 W,2021-05-03,Method of titrating dose of psychedelics,,MIND MEDICINE INC;;BARROW ROBERT;;KARLIN DANIEL R,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/175-633-970-628-63X,Patent Application,no,0,0,5,5,0,A61K31/4045;;A61P25/00;;A61K31/48;;A61K31/675;;A61K31/137;;A61P25/00;;A61K31/4045;;A61K31/675;;A61K31/137;;A61K31/48,A61K31/137;;A61K31/4045;;A61K31/48;;A61K31/675;;A61P25/00,,0,0,,,,PENDING
16,US,A1,US 2022/0362237 A1,111-120-284-980-347,2022-11-17,2022,US 202217877521 A,2022-07-29,US 202217877521 A;;US 202217732878 A;;US 202163183578 P,2021-05-03,PSYCHEDELICS FOR TREATMENT OF PAIN,"A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual. A method of treating a pain syndrome, by administering an effective amount of a psychedelic to an individual, and providing a central effect, an effect on depression, and an inflammatory effect.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/111-120-284-980-347,Patent Application,yes,0,1,1,4,0,A61K31/675;;A61K31/17;;A61K31/4045;;A61K31/48;;A61K31/48;;A61K31/17;;A61K31/4045;;A61K31/675,A61K31/48;;A61K31/17;;A61K31/4045;;A61K31/675,,0,0,,,,PENDING
17,IL,A,IL 308069 A,175-752-686-844-943,2023-12-01,2023,IL 30806923 A,2023-10-26,US 202163184703 P;;US 2022/0027180 W,2021-05-05,Mdma enantiomers,,MIND MEDICINE INC;;BARROW ROBERT;;KARLIN DANIEL R,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/175-752-686-844-943,Patent Application,no,0,0,7,10,0,A61K31/36;;A61P25/28;;A61K31/36;;A61K45/06;;A61P25/28;;A61K31/36;;A61P25/28;;A61K45/06,A61K31/36;;A61K45/06;;A61P25/28,,0,0,,,,PENDING
18,US,A1,US 2022/0409628 A1,086-149-039-416-19X,2022-12-29,2022,US 202217835051 A,2022-06-08,US 202217835051 A;;US 202163216118 P,2021-06-29,18-MC FOR TREATING OBESITY,"A method of treating obesity, by administering an effective amount of a composition chosen from the group consisting of 18-methoxycoronaridine (18-MC), salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof to an individual and treating obesity. A method of treating binge eating, by administering an effective amount of the composition to an individual and treating binge eating. A method of treating behavioral addictions, by administering an effective amount of the composition to an individual and treating the behavioral addiction.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,MIND MEDICINE INC (2021-06-22),https://lens.org/086-149-039-416-19X,Patent Application,yes,1,0,2,2,0,A61P25/30;;A61P3/04;;A61K31/55;;A61K31/55;;A61P25/30;;A61P3/04,A61K31/55;;A61P3/04;;A61P25/30,,1,1,014-726-654-498-487,pmc3787601;;10.1007/s00213-008-1290-9;;18751969,"Taraschenko, O.D., Rubbinaccio, H.Y., Maisonneuve, I.M. et al. 18-Methoxycoronaridine: a potential new treatment for obesity in rats?. Psychopharmacology 201, 339–350 (2008). https://doi.org/10.1007/s00213-008-1290-9 (Year: 2008)",PENDING
19,TW,A,TW 202245747 A,188-048-918-560-986,2022-12-01,2022,TW 111116662 A,2022-05-03,US 202163184703 P,2021-05-05,MDMA enantiomers,"A composition for use in psychotherapeutic or medical treatment of an R(-) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/188-048-918-560-986,Patent of Addition,no,0,0,7,10,0,A61K31/36;;A61P25/28;;A61K31/36;;A61K45/06;;A61P25/28;;A61K31/36;;A61P25/28;;A61K45/06,A61K31/36;;A61P25/00;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28,,0,0,,,,PENDING
20,WO,A1,WO 2022/265878 A1,084-280-436-093-567,2022-12-22,2022,US 2022/0032401 W,2022-06-06,US 202163210346 P,2021-06-14,CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION,"A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminating its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug. A method of stopping psychosis due to psychedelic administration, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug, and stopping psychosis caused by the psychedelic drug.",MIND MEDICINE INC,KARLIN DANIEL R;;BARROW ROBERT,,https://lens.org/084-280-436-093-567,Patent Application,yes,4,0,3,3,0,A61K31/48;;A61P25/00;;A61P25/00;;A61K31/48,A61K31/48;;A61K31/17;;A61K31/4465;;A61K45/00,,0,0,,,,PENDING
21,AU,A1,AU 2022/268891 A1,173-610-177-067-932,2023-11-09,2023,AU 2022/268891 A,2022-05-01,US 202163183579 P;;US 2022/0027179 W,2021-05-03,METHOD OF TITRATING DOSE OF PSYCHEDELICS,"A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/173-610-177-067-932,Patent Application,no,0,0,5,5,0,A61K31/4045;;A61P25/00;;A61K31/48;;A61K31/675;;A61K31/137;;A61P25/00;;A61K31/4045;;A61K31/675;;A61K31/137;;A61K31/48,A61P25/00;;A61K31/4045;;A61K31/407;;A61K31/437,,0,0,,,,PENDING
22,US,A1,US 2023/0226019 A1,024-640-014-009-791,2023-07-20,2023,US 202318186494 A,2023-03-20,US 202318186494 A;;US 202217734100 A;;US 202163184703 P,2021-05-05,MDMA ENANTIOMERS,"A composition for use in psychotherapeutic or medical treatment of an R(−) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,MIND MEDICINE INC (2021-05-13),https://lens.org/024-640-014-009-791,Patent Application,yes,0,0,1,10,0,A61P25/00;;A61K31/36;;A61K31/198;;A61K31/36;;A61P25/00;;A61K47/542,A61K31/36;;A61K47/54;;A61P25/00,,0,0,,,,PENDING
23,WO,A1,WO 2023/278108 A1,164-388-880-917-619,2023-01-05,2023,US 2022/0032601 W,2022-06-08,US 202163216118 P,2021-06-29,18-MC FOR TREATING OBESITY,"A method of treating obesity, by administering an effective amount of a composition chosen from the group consisting of 18-methoxycoronaridine (18-MC), salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof to an individual and treating obesity. A method of treating binge eating, by administering an effective amount of the composition to an individual and treating binge eating. A method of treating behavioral addictions, by administering an effective amount of the composition to an individual and treating the behavioral addiction.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/164-388-880-917-619,Patent Application,yes,4,0,2,2,0,A61P25/30;;A61P3/04;;A61K31/55;;A61K31/55;;A61P25/30;;A61P3/04,A61K31/33;;A61K31/00;;A61K31/41;;A61K31/433,,0,0,,,,PENDING
24,AU,A1,AU 2022/269557 A1,174-303-760-548-262,2023-11-09,2023,AU 2022/269557 A,2022-05-01,US 202163184703 P;;US 2022/0027180 W,2021-05-05,MDMA ENANTIOMERS,"A composition for use in psychotherapeutic or medical treatment of an R(-) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/174-303-760-548-262,Patent Application,no,0,0,7,10,0,A61K31/36;;A61P25/28;;A61K31/36;;A61K45/06;;A61P25/28;;A61K31/36;;A61P25/28;;A61K45/06,C07C231/02,,0,0,,,,PENDING
25,CA,A1,CA 3216939 A1,024-600-444-149-691,2022-11-10,2022,CA 3216939 A,2022-05-01,US 202163183579 P;;US 2022/0027179 W,2021-05-03,METHOD OF TITRATING DOSE OF PSYCHEDELICS,"A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/024-600-444-149-691,Patent Application,no,0,0,5,5,0,A61K31/4045;;A61P25/00;;A61K31/48;;A61K31/675;;A61K31/137;;A61P25/00;;A61K31/4045;;A61K31/675;;A61K31/137;;A61K31/48,A61K31/4045;;A61K31/437,,0,0,,,,PENDING
26,CA,A1,CA 3217362 A1,055-829-611-892-918,2022-11-10,2022,CA 3217362 A,2022-05-01,US 202163184703 P;;US 2022/0027180 W,2021-05-05,MDMA ENANTIOMERS,"A composition for use in psychotherapeutic or medical treatment of an R(-) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/055-829-611-892-918,Patent Application,no,0,0,7,10,0,A61K31/36;;A61P25/28;;A61K31/36;;A61K45/06;;A61P25/28;;A61K31/36;;A61P25/28;;A61K45/06,C07C231/02,,0,0,,,,PENDING
27,WO,A1,WO 2022/235530 A1,137-617-675-978-874,2022-11-10,2022,US 2022/0027180 W,2022-05-01,US 202163184703 P,2021-05-05,MDMA ENANTIOMERS,"A composition for use in psychotherapeutic or medical treatment of an R(-) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(-) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,,https://lens.org/137-617-675-978-874,Patent Application,yes,7,3,7,10,0,A61K31/36;;A61P25/28;;A61K31/36;;A61K45/06;;A61P25/28;;A61K31/36;;A61P25/28;;A61K45/06,C07C231/02,,1,1,076-506-896-151-659,10.1007/s00213-017-4812-5;;29248945,"PITTS ET AL.: ""+/-)-MDMA and Its Enantiomers: Potential Therapeutic Advantages of R(-)-MDMA"", PSYCHOPHARMACOLOGY, vol. 235, no. 2, 16 December 2017 (2017-12-16), pages 377 - 392, XP036477501, DOI: https://doi.org/10.1007/s00213-017-4812-5.",PENDING
28,US,A1,US 2022/0354831 A1,073-704-780-024-517,2022-11-10,2022,US 202217734102 A,2022-05-01,US 202217734102 A;;US 202163183771 P,2021-05-04,MOVEMENT DISORDERS,"A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,MIND MEDICINE INC (2021-05-13),https://lens.org/073-704-780-024-517,Patent Application,yes,2,0,3,4,0,A61P25/14;;A61K31/437;;A61K31/4045;;A61K31/137;;A61K31/36;;A61K31/48;;A61K31/675;;A61K31/437;;A61P25/14;;A61K45/06;;A61K31/4045,A61K31/437;;A61K31/4045;;A61K45/06;;A61P25/14,,0,0,,,,PENDING
29,US,A1,US 2022/0395499 A1,074-013-008-000-804,2022-12-15,2022,US 202217833829 A,2022-06-06,US 202217833829 A;;US 202163210346 P,2021-06-14,CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION,"A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminating its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug. A method of stopping psychosis due to psychedelic administration, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug, and stopping psychosis caused by the psychedelic drug.",MIND MEDICINE INC,KARLIN DANIEL R;;BARROW ROBERT,MIND MEDICINE INC (2021-06-22),https://lens.org/074-013-008-000-804,Patent Application,yes,0,1,3,3,0,A61K31/48;;A61P25/00;;A61P25/00;;A61K31/48,A61K31/48;;A61P25/00,,0,0,,,,PENDING
30,US,A1,US 2023/0226020 A1,140-365-577-097-459,2023-07-20,2023,US 202318186764 A,2023-03-20,US 202318186764 A;;US 202217734100 A;;US 202163184703 P,2021-05-05,MDMA ENANTIOMERS,"A composition for use in psychotherapeutic or medical treatment of an R(−) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R,MIND MEDICINE INC (2021-05-13),https://lens.org/140-365-577-097-459,Patent Application,yes,0,0,1,10,0,A61K31/36;;A61P25/22;;A61P25/28;;A61K31/198;;A61K31/36;;A61P25/28;;A61P25/22;;A61K47/55,A61K31/36;;A61K47/55;;A61P25/22;;A61P25/28,,0,0,,,,PENDING
31,EP,A1,EP 2833346 A1,128-736-567-300-13X,2015-02-04,2015,EP 14178719 A,2014-07-28,GB 201313510 A,2013-07-29,Coated object,"A graphic display sheet (3) or other object has a micro vacuum receptor layer (9) on one side, for attachment to a micro suction layer (7). The micro vacuum receptor layer (9) is provided by a high gloss, silicone free, polyester-based varnish. In the case of the graphic display sheet (3), a printed display side (11) is opposite to the micro vacuum receptor layer (9).
",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/128-736-567-300-13X,Patent Application,yes,4,0,10,20,0,A41F1/00;;A47G1/17;;A63H33/04;;F16B47/00;;G09F7/18;;G09F15/02;;G09F15/02;;G09F1/10;;G09F7/18;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F15/02;;G09F1/10;;G09F7/18,,0,0,,,,ACTIVE
32,EP,B1,EP 2833346 B1,040-033-288-929-961,2018-02-14,2018,EP 14178719 A,2014-07-28,GB 201313510 A,2013-07-29,Coated object,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/040-033-288-929-961,Granted Patent,yes,1,0,10,20,0,A41F1/00;;A47G1/17;;A63H33/04;;F16B47/00;;G09F7/18;;G09F15/02;;G09F15/02;;G09F1/10;;G09F7/18;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F15/02;;G09F1/10;;G09F7/18,,0,0,,,,ACTIVE
33,PL,T3,PL 2898499 T3,169-293-465-043-803,2017-09-29,2017,PL 13771174 T,2013-09-20,GB 201216894 A;;GB 201313510 A,2012-09-21,DISPLAY SUBSTRATE,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/169-293-465-043-803,Patent Application,no,0,0,6,20,0,G09F1/10;;G09F2007/1852;;F16B47/003;;G09F15/02;;G09F2007/1852;;G09F1/10;;F16B47/003;;G09F15/02;;G09F7/18,G09F1/10;;G09F15/02;;G09F7/18,,0,0,,,,PENDING
34,GB,B,GB 2516665 B,030-787-720-553-149,2015-10-14,2015,GB 201313510 A,2013-07-29,GB 201313510 A,2013-07-29,Graphic display sheet with micro vacuum receptor layer,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/030-787-720-553-149,Granted Patent,no,3,0,10,20,0,A41F1/00;;A47G1/17;;A63H33/04;;F16B47/00;;G09F7/18;;G09F15/02;;G09F15/02;;G09F1/10;;G09F7/18;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F7/18;;A47G1/17,,0,0,,,,ACTIVE
35,GB,A,GB 2506146 A,120-252-295-467-179,2014-03-26,2014,GB 201216894 A,2012-09-21,GB 201216894 A,2012-09-21,Micro suction graphic display system,"A display system comprises a display substrate 2, including an adhesive layer 5 or other means for attachment to a wall 1, and a micro suction layer 7. A graphic display sheet 3 has a micro vacuum receptor layer 9 on one side that may be provided by a varnish, and a printed display side 11 opposite to the micro vacuum receptor layer. The receptor layer sticks to, and is removable from, the micro suction layer of the display substrate. Thus, the graphic display sheet 3 can be changed without requiring additional micro suction material. Preferably the varnish providing the micro vacuum receptor layer is a silicone free polyurethane based lacquer. There may be release papers 4, 8 attached to the adhesive layer 5 and micro suction layer 7.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYNN;;BARROW LASCELLE,,https://lens.org/120-252-295-467-179,Patent Application,no,5,1,4,20,0,F16B47/00;;F16B47/003;;F16B47/003;;G09F1/10;;G09F15/02;;G09F1/10;;G09F15/02;;G09F2007/1852,F16B47/00,,2,0,,,"Suction cup tape, Inventables.com, 20 May 2012, available at: http://web.archive.org/web/20120520194206/https://www.inventables.com/technologies/suction-cup-tape;;""Water Base Polyurethane Manufacturers"", Bond Polymers International, Sept 2008. Available at http://web.archive.org/web/20080929083641/http://www.bondpolymers.com/ [Accessed 04/04/13]",ACTIVE
36,ES,T3,ES 2621233 T3,070-196-780-225-653,2017-07-03,2017,ES 13771174 T,2013-09-20,GB 201216894 A;;GB 201313510 A;;GB 2013052468 W,2012-09-21,Sustrato de visualización,"Un sistema de visualización que comprende: a. Un sustrato de visualización (2) que comprende: una capa adhesiva (5) u otros medios para unir a una pared (1), y una capa de micro succión (7); y b. una lámina de visualización gráfica (3) para la unión extraíble a la capa de micro succión (7), teniendo un lado de visualización impreso (11); caracterizado por el hecho de que la lámina de visualización gráfica (3) tiene una capa receptora de micro vacío (9) proporcionada mediante un barniz exento de silicona solamente en un lado de un material base (10) de la lámina de visualización gráfica opuesta al lado de visualización impreso (11), para la unión extraíble a la capa de micro succión (7).",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/070-196-780-225-653,Granted Patent,no,0,0,6,20,0,G09F1/10;;G09F2007/1852;;F16B47/003;;G09F15/02;;G09F2007/1852;;G09F1/10;;F16B47/003;;G09F15/02;;G09F7/18,G09F15/02;;G09F1/10;;G09F7/18,,0,0,,,,ACTIVE
37,PL,T3,PL 2833346 T3,096-081-260-030-944,2018-08-31,2018,PL 14178719 T,2014-07-28,GB 201313510 A;;EP 14178719 A,2013-07-29,Coated object,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/096-081-260-030-944,Patent Application,no,0,0,10,20,0,A41F1/00;;A47G1/17;;A63H33/04;;F16B47/00;;G09F7/18;;G09F15/02;;G09F15/02;;G09F1/10;;G09F7/18;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F15/02;;G09F1/10;;G09F7/18,,0,0,,,,PENDING
38,GB,B,GB 2525522 B,054-195-884-723-660,2016-08-03,2016,GB 201512843 A,2013-07-29,GB 201512843 A;;GB 201313510 A,2013-07-29,Object with micro vacuum receptor layer,,AUGUSTUS MARTIN LTD,DANIEL PATTISON;;GLYN STOKES;;LASCELLE BARROW,,https://lens.org/054-195-884-723-660,Granted Patent,no,4,0,10,20,0,A41F1/00;;A47G1/17;;A63H33/04;;F16B47/00;;G09F7/18;;G09F15/02;;G09F15/02;;G09F1/10;;G09F7/18;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F15/02;;A41F1/00;;A63H33/04;;F16B47/00,,3,0,,,"""Miniot Case for iPad2"", Miniot BV; 10 May 2012. See https://web.archive.org/web/20120510213131/https://www.miniot.com/webshop/?portlet=miniot&page=miniotcase&state=normal;;""Miniot book for iPhone 5"", Miniot BV; 1 July 2013. See http://www.miniot.com/webshop/support/MiniotBookFlyer.pdf;;""Industrial Finishing - Wood. Facts and Figures"" Akzo-Nobel, 2003. See https://www.akzonobel.com/wood/ee/system/images/AkzoNobel_Industrial_Finishing_Wood_Facts_and_Figures_tcm125-34902.pdf",INACTIVE
39,GB,A,GB 2525522 A,091-885-842-059-706,2015-10-28,2015,GB 201512843 A,2013-07-29,GB 201512843 A;;GB 201313510 A,2013-07-29,Object with micro vacuum receptor layer,"An object other than a graphic display sheet has a micro vacuum receptor layer on at least one side, for attachment to a micro suction layer. The micro vacuum receptor layer surface is provided by a high gloss, silicone free, polyester-based varnish. The micro vacuum receptor layer may be provided on a container, an element of a childs toy or a fastener, e.g. a garment fastener, where they are required to be temporarily fixed to another flat surface, that surface being provided with a micro suction layer.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/091-885-842-059-706,Patent Application,no,3,0,10,20,0,A41F1/00;;A47G1/17;;A63H33/04;;F16B47/00;;G09F7/18;;G09F15/02;;G09F15/02;;G09F1/10;;G09F7/18;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F15/02;;A41F1/00;;A63H33/04;;F16B47/00,,2,0,,,"""Miniot Case for iPad2"", Miniot BV; 10 May 2012. See https://web.archive.org/web/20120510213131/https://www.miniot.com/webshop/?portlet=miniot&page=miniotcase&state=normal;;""Miniot book for iPhone 5"", Miniot BV; 1 July 2013. See http://www.miniot.com/webshop/support/MiniotBookFlyer.pdf",INACTIVE
40,WO,A1,WO 2014/045050 A1,167-031-763-291-415,2014-03-27,2014,GB 2013052468 W,2013-09-20,GB 201216894 A;;GB 201313510 A,2012-09-21,DISPLAY SUBSTRATE,"A display system comprises a display substrate (2), including an adhesive layer or other means for attachment to a wall (1), and a micro suction layer (7). A graphic display sheet (3) has a micro vacuum receptor layer (9) provided by a varnish on one side, for removable attachment to the micro suction layer (7), and a printed display side (11) opposite to the micro vacuum receptor layer. Thus, the graphic display sheet (3) can be changed without requiring additional micro suction material.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/167-031-763-291-415,Patent Application,yes,4,1,6,20,0,G09F1/10;;G09F2007/1852;;F16B47/003;;G09F15/02;;G09F2007/1852;;G09F1/10;;F16B47/003;;G09F15/02;;G09F7/18,G09F1/10;;G09F15/02;;G09F7/18,,0,0,,,,PENDING
41,ES,T3,ES 2663336 T3,021-425-633-202-231,2018-04-12,2018,ES 14178719 T,2014-07-28,GB 201313510 A,2013-07-29,Objeto recubierto,"Un método de unir temporalmente un objeto a una pared, que comprende unir una capa de micro succión a la pared, aplicar un barniz basado en poliéster sin silicona, brillante en al menos una superficie plana del objeto, para proporcionar una capa receptora de micro vacío, y unir el objeto a la capa de micro succión utilizando la capa receptora de micro vacío.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/021-425-633-202-231,Granted Patent,no,0,0,10,20,0,A41F1/00;;A47G1/17;;A63H33/04;;F16B47/00;;G09F7/18;;G09F15/02;;G09F15/02;;G09F1/10;;G09F7/18;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F15/02;;G09F1/10;;G09F7/18,,0,0,,,,ACTIVE
42,EP,B1,EP 2898499 B1,171-003-257-708-448,2016-12-28,2016,EP 13771174 A,2013-09-20,GB 201216894 A;;GB 201313510 A;;GB 2013052468 W,2012-09-21,DISPLAY SUBSTRATE,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/171-003-257-708-448,Granted Patent,yes,1,0,6,20,0,G09F1/10;;G09F2007/1852;;F16B47/003;;G09F15/02;;G09F2007/1852;;G09F1/10;;F16B47/003;;G09F15/02;;G09F7/18,G09F15/02;;G09F1/10;;G09F7/18,,0,0,,,,ACTIVE
43,US,A1,US 2015/0248853 A1,009-373-730-213-024,2015-09-03,2015,US 201314428191 A,2013-09-20,GB 201216894 A;;GB 201313510 A;;GB 2013052468 W,2012-09-21,DISPLAY SUBSTRATE,"A display system comprises a display substrate ( 2 ), including an adhesive layer or other means for attachment to a wall ( 1 ), and a micro suction layer ( 7 ). A graphic display sheet ( 3 ) has a micro vacuum receptor layer ( 9 ) provided by a varnish on one side, for removable attachment to the micro suction layer ( 7 ), and a printed display side ( 11 ) opposite to the micro vacuum receptor layer. Thus, the graphic display sheet ( 3 ) can be changed without requiring additional micro suction material.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,AUGUSTUS MARTIN LIMITED (2015-10-06),https://lens.org/009-373-730-213-024,Patent Application,yes,21,2,6,20,0,G09F1/10;;G09F2007/1852;;F16B47/003;;G09F15/02;;G09F2007/1852;;G09F1/10;;F16B47/003;;G09F15/02;;G09F7/18,G09F15/02;;G09F7/18,,1,0,,,"Inventables, Suction Cup Tape, 2001 August 17, https://web.archive.org/web/20110817004514/http://www.inventables.com/technologies/suction-cup-tape",DISCONTINUED
44,GB,B,GB 2506146 B,135-872-194-991-301,2016-07-06,2016,GB 201216894 A,2012-09-21,GB 201216894 A,2012-09-21,Display substrate,,AUGUSTUS MARTIN LTD,DANIEL PATTISON;;GLYN STOKES;;LASCELLE BARROW,,https://lens.org/135-872-194-991-301,Granted Patent,no,5,0,4,20,0,F16B47/00;;F16B47/003;;F16B47/003;;G09F1/10;;G09F15/02;;G09F1/10;;G09F15/02;;G09F2007/1852,G09F15/02;;F16B47/00;;G09F1/10,,2,0,,,"Suction cup tape, Inventables.com, 20 May 2012, available at: http://web.archive.org/web/20120520194206/https://www.inventables.com/technologies/suction-cup-tape;;""Water Base Polyurethane Manufacturers"", Bond Polymers International, Sept 2008. Available at http://web.archive.org/web/20080929083641/http://www.bondpolymers.com/ [Accessed 04/04/13]",ACTIVE
45,EP,A1,EP 2898499 A1,179-120-814-186-130,2015-07-29,2015,EP 13771174 A,2013-09-20,GB 201216894 A;;GB 201313510 A;;GB 2013052468 W,2012-09-21,DISPLAY SUBSTRATE,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/179-120-814-186-130,Patent Application,yes,0,0,6,20,0,G09F1/10;;G09F2007/1852;;F16B47/003;;G09F15/02;;G09F2007/1852;;G09F1/10;;F16B47/003;;G09F15/02;;G09F7/18,G09F15/02;;G09F1/10;;G09F7/18,,0,0,,,,ACTIVE
46,GB,A,GB 2516665 A,074-014-162-372-176,2015-02-04,2015,GB 201313510 A,2013-07-29,GB 201313510 A,2013-07-29,Coated object,"A display system comprises a display substrate 2, including an adhesive layer 5 or other means for attachment to a wall 1, and a micro suction layer 7. A graphic display sheet 3 has a micro vacuum receptor layer 9 on one side that may be provided by a varnish, and a printed display side 11 opposite to the micro vacuum receptor layer. The micro vacuum receptor layer 9 is provided by a high gloss, silicone free, polyester-based varnish. In the case of the graphic display sheet, a printed display side is opposite to the micro vacuum receptor layer. The receptor layer sticks to, and is removable from, the micro suction layer of the display substrate. Thus, the graphic display sheet 3 can be changed without requiring additional micro suction material. There may be release papers 4, 8 attached to the adhesive layer 5 and micro suction layer 7.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/074-014-162-372-176,Patent Application,no,3,0,10,20,0,A41F1/00;;A47G1/17;;A63H33/04;;F16B47/00;;G09F7/18;;G09F15/02;;G09F15/02;;G09F1/10;;G09F7/18;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F7/18;;A47G1/17,,0,0,,,,ACTIVE
47,EP,A1,EP 3107081 A1,124-659-025-569-474,2016-12-21,2016,EP 16174370 A,2016-06-14,GB 201510475 A,2015-06-16,ADVERTISING DISPLAYS,"A box 2 for use in a display arrangement contains at least one magnet 8 for magnetically attaching an attachment face 4 of the box to a background graphic sheet. At least one display face 6 of the box 2 is provided with a micro suction layer 14 for supporting a graphic element. A display apparatus including the box 2 comprises a background substrate, including an adhesive layer or other means for attachment to a metallic backboard, and a micro suction layer on a side opposite the attachment means. The background graphic sheet has a smooth side for attachment to the micro suction layer, and a graphic on an opposite side of the sheet.
",AUGUSTUS MARTIN LTD,STOKES GLYN;;PATTISON DANIEL;;BARROW LASCELLE,,https://lens.org/124-659-025-569-474,Patent Application,yes,4,0,3,3,0,G09F1/10;;G09F7/04;;G09F7/04;;G09F7/12;;G09F7/12;;G09F7/18;;G09F15/02;;G09F2007/122;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F1/10;;G09F7/04;;G09F7/12;;G09F7/18;;G09F15/02,,0,0,,,,DISCONTINUED
48,GB,A,GB 2539419 A,122-569-564-003-099,2016-12-21,2016,GB 201510475 A,2015-06-16,GB 201510475 A,2015-06-16,Advertising Displays,"A box 2 for use in a display arrangement contains at least one magnet 8 for magnetically attaching an attachment face 4 of the box to a background graphic sheet (22, Fig. 2). At least one display face 6 of the box 2 is provided with a micro suction layer 14 for supporting a graphic element. A display apparatus including the box 2 comprises a background substrate, including an adhesive laver or other means for attachment to a metallic backboard (18, Fig. 2), and a micro suction layer on a side opposite the attachment means. The background graphic sheet has a smooth side for attachment to the micro suction layer, and a graphic on an opposite side of the sheet. The box may have multiple attachment faces and display faces so that it can be used in different orientations and multiple boxes of different sizes may be attached to the background sheet. The apparatus provides an attractive reconfigurable display with a three-dimensional appearance.",AUGUSTUS MARTIN LTD,GLYNN STOKES;;DANIEL PATTISON;;LASCELLE AUGUSTUS BARROW,,https://lens.org/122-569-564-003-099,Patent Application,no,7,0,3,3,0,G09F1/10;;G09F7/04;;G09F7/04;;G09F7/12;;G09F7/12;;G09F7/18;;G09F15/02;;G09F2007/122;;G09F2007/122;;G09F2007/1852;;G09F2007/1852,G09F7/04;;G09F7/12,,0,0,,,,DISCONTINUED
49,US,A1,US 2023/0301985 A1,078-673-394-175-23X,2023-09-28,2023,US 202318197892 A,2023-05-16,US 202318197892 A;;US 202217734102 A;;US 202163183771 P,2021-05-04,MOVEMENT DISORDERS,"A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R;;SMAGIN GENNADY,MIND MEDICINE INC (2021-05-07),https://lens.org/078-673-394-175-23X,Patent Application,yes,0,0,1,4,0,A61P25/00;;A61K31/36;;A61K31/437;;A61K31/48;;A61K31/48;;A61K31/437;;A61P25/00;;A61K31/36,A61K31/48;;A61K31/36;;A61K31/437;;A61P25/00,,0,0,,,,PENDING
50,GB,A,GB 2497683 A,029-816-813-960-004,2013-06-19,2013,GB 201301768 A,2011-02-02,GB 201301768 A,2011-02-02,Hanger for hanging display material,"A hanger for hanging a substrate 3 bearing indicia comprises an elongate stabiliser bar 101 which has integrally formed with it a pair of mutually spaced bar suspension elements 7, 9 each for suspension by a filament or rod 10, and two hook-like substrate engagement elements (106, Fig. 6), spaced longitudinally on the stabiliser bar to engage apertures in the substrate. Another integral part 102 of the stabiliser bar provides an additional connection of the bar to the filament or rod 10. The stabiliser bar is preferably flexible so that it is bowed when the substrate is hung from it to impart tension to and rigidify the substrate.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;ASLET PETER;;STOKES GLYNN;;BARROW LASCELLE,,https://lens.org/029-816-813-960-004,Patent Application,no,2,0,3,3,0,G09F7/18;;G09F2007/186;;G09F1/10;;G09F2007/186,G09F7/18,,0,0,,,,INACTIVE
51,GB,B,GB 2456920 B,134-604-627-782-517,2010-08-25,2010,GB 0901705 A,2009-02-02,GB 0801852 A,2008-02-01,Hanging of display matter,,AUGUSTUS MARTIN LTD,SNEDDON STUART;;STOKES GLYNN;;PATTISON DANIEL;;BARROW LASCELLE,,https://lens.org/134-604-627-782-517,Granted Patent,no,4,1,4,7,0,A47G1/18;;G09F7/18;;G09F15/0018;;G09F7/18;;G09F2007/186,G09F7/18;;A47G1/18;;G09F15/00,,0,0,,,,INACTIVE
52,GB,B,GB 2467233 B,082-196-643-925-931,2010-12-29,2010,GB 201001159 A,2009-02-02,GB 0801852 A;;GB 0901705 A,2008-02-01,Hanging of display matter,,AUGUSTUS MARTIN LTD,BARROW LASCELLE;;PATTISON DANIEL;;STOKES GLYNN;;SNEDDON STUART,,https://lens.org/082-196-643-925-931,Granted Patent,no,5,0,3,7,0,G09F7/18;;G09F7/18;;G09F2007/186,G09F7/18,,0,0,,,,INACTIVE
53,EP,B1,EP 2671212 B1,150-421-265-268-999,2015-03-18,2015,EP 12703045 A,2012-01-31,GB 201101796 A;;EP 2012051598 W,2011-02-02,HANGERS FOR DISPLAY MATERIAL,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;ASLET PETER;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/150-421-265-268-999,Granted Patent,yes,3,0,7,7,0,G09F7/18;;G09F2007/186;;G09F7/18;;G09F2007/186,G09F7/18,,0,0,,,,ACTIVE
54,GB,B,GB 2477144 B,187-007-099-241-545,2012-02-29,2012,GB 201001145 A,2010-01-25,GB 201001145 A,2010-01-25,Hanging display material,,AUGUSTUS MARTIN LTD,BARROW LASCELLE;;PATTISON DANIEL;;STOKES GLYNN;;SNEDDON STUART,,https://lens.org/187-007-099-241-545,Granted Patent,no,7,0,3,3,0,G09F1/04;;G09F1/10;;G09F7/18;;G09F1/10;;G09F1/04;;G09F3/08;;G09F7/18;;G09F2007/186,G09F1/04;;G09F1/10;;G09F7/18,,0,0,,,,INACTIVE
55,GB,A,GB 2456920 A,090-825-941-502-944,2009-08-05,2009,GB 0901705 A,2009-02-02,GB 0801852 A,2008-02-01,Hanging bar having a pair of bar suspension artifacts and two substrate engagement artifacts for supporting a substrate,"A hanging bar is disclosed which comprises an elongate, stabiliser bar 20 which incorporates as integral parts of the bar a pair of mutually spaced bar suspension artifacts 26,28 (e.g. dome-shaped deformations), and two substrate engagement artifacts (21 ,Fig.1) (e.g. hooks) mutually spaced longitudinally of the stabiliser bar and integral therewith, wherein the substrate engagement hooks engage with apertures 18,19 in a substrate 12. Alternatively, in another arrangement (Fig.6) the substrate has a fixed first distance between its said apertures, and the hanging aid comprises an elongate, stabiliser bar (222) with a modulus of elasticity permitting it to be manually bowed, at least one suspension artifact (226) for use in supporting the bar, and two substrate engagement artifacts 223,224 (e.g. hooks) mutually spaced longitudinally of the unstressed bar by a fixed second distance that is marginally greater than the said fixed first distance between the substrate's said apertures. The stabilizer bar is arcuately bendable manually to permit engagement of the engagement hooks into the substrate apertures and, upon release, to engage resiliently the substrate without tearing the apertures.",AUGUSTUS MARTIN LTD,SNEDDON STUART;;STOKES GLYNN;;PATTISON DANIEL;;BARROW LASCELLE,,https://lens.org/090-825-941-502-944,Patent Application,no,4,5,4,7,0,A47G1/18;;G09F7/18;;G09F15/0018;;G09F7/18;;G09F2007/186,G09F7/18;;A47G1/18;;G09F15/00,,0,0,,,,INACTIVE
56,EP,A1,EP 2667373 A1,064-255-332-607-519,2013-11-27,2013,EP 12168780 A,2012-05-22,EP 12168780 A,2012-05-22,Posters,"A poster and a poster alignment system. An alignment element has a plurality of lugs. A poster provided in a plurality of sections (20-23) has a plurality of openings (30-38) adjacent an edge of the poster, so as to achieve correct alignment of the poster in a viewing position by placing at least some of the openings (30-38) around at least some of the lugs. Each section (20-23) has some of the openings (30-38), and the openings of each section are configured differently from the openings of the other section(s).
",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;BARROW LASCELLE;;ASLET PETER;;STOKES GLYNN,,https://lens.org/064-255-332-607-519,Patent Application,yes,3,0,1,1,0,G09F15/0012;;G09F15/0025;;G09F15/02,G09F15/00;;G09F15/02,,0,0,,,,DISCONTINUED
57,GB,B,GB 2497683 B,084-436-705-627-378,2013-10-30,2013,GB 201301768 A,2011-02-02,GB 201301768 A,2011-02-02,Hangers for display material,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;ASLET PETER;;STOKES GLYNN;;BARROW LASCELLE,,https://lens.org/084-436-705-627-378,Granted Patent,no,2,0,3,3,0,G09F7/18;;G09F2007/186;;G09F1/10;;G09F2007/186,G09F7/18,,0,0,,,,INACTIVE
58,GB,A,GB 2489235 A,186-560-259-134-093,2012-09-26,2012,GB 201104710 A,2011-03-21,GB 201104710 A,2011-03-21,Stand for flexible display material.,"A stand for retaining flexible display material comprises a base 1 and front and rear holding members 2, 3. The holding members are formed from shaped elongate elements, each having two ends both of which are attached to the base and are curved when viewed from above. A curved slot is formed between the holding members and this imparts a curvature to the display material, which acts to rigidify it. There may be more than one front holding member and/or more than one rear holding member. The holding members are preferably formed from lengths of wire and differ in height. A number of holding members may be provided on a single base for retaining a plurality of display sheets, and the holding members may be arranged to form concave (Fig. 4) or convex (Fig. 6) display surfaces.",AUGUSTUS MARTIN LTD,STOKES GLYNN;;PATTISON DANIEL;;ASLET PETER;;BARROW LASCELLE,,https://lens.org/186-560-259-134-093,Patent Application,no,6,2,3,3,0,A47G1/14;;G09F1/10;;G09F15/00;;G09F2001/106;;G09F15/0056;;G09F1/065;;G09F1/10,G09F1/10;;G09F15/00,,2,0,,,"""Menu Holder Stand Display Acrylic Menu Stand""; Ruisen Manufacturing Co. 29 April 2011. See http://webcache.googleusercontent.com/search?q=cache:DSBT7PhIh6QJ:www.alibaba.com/product-gs/317120446/Menu_Holder_Stand_Display_Acrylic_Menu.html;;""A Very Good Set of Four Antique Edwardian English Sterling Silver Wishbone Menu Holders - Boxed""; myfamilysilver.com. 21 July 2010. See http://www.myfamilysilver.com/pages/viewItem.aspx?id=15315",INACTIVE
59,EP,A1,EP 2671212 A1,196-290-628-320-234,2013-12-11,2013,EP 12703045 A,2012-01-31,GB 201101796 A;;EP 2012051598 W,2011-02-02,HANGERS FOR DISPLAY MATERIAL,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;ASLET PETER;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/196-290-628-320-234,Patent Application,yes,0,0,7,7,0,G09F7/18;;G09F2007/186;;G09F7/18;;G09F2007/186,G09F7/18,,1,0,,,See references of WO 2012104317A1,ACTIVE
60,GB,B,GB 2489235 B,148-600-899-375-392,2013-03-13,2013,GB 201104710 A,2011-03-21,GB 201104710 A,2011-03-21,Stands for display material,,AUGUSTUS MARTIN LTD,STOKES GLYNN;;PATTISON DANIEL;;ASLET PETER;;BARROW LASCELLE,,https://lens.org/148-600-899-375-392,Granted Patent,no,6,0,3,3,0,A47G1/14;;G09F1/10;;G09F15/00;;G09F2001/106;;G09F15/0056;;G09F1/065;;G09F1/10,G09F1/10;;A47G1/14;;G09F15/00,,2,0,,,"""Menu Holder Stand Display Acrylic Menu Stand""; Ruisen Manufacturing Co. 29 April 2011. See http://webcache.googleusercontent.com/search?q=cache:DSBT7PhIh6QJ:www.alibaba.com/product-gs/317120446/Menu_Holder_Stand_Display_Acrylic_Menu.html;;""A Very Good Set of Four Antique Edwardian English Sterling Silver Wishbone Menu Holders - Boxed""; myfamilysilver.com. 21 July 2010. See http://www.myfamilysilver.com/pages/viewItem.aspx?id=15315",INACTIVE
61,GB,A,GB 2467233 A,198-041-767-873-440,2010-07-28,2010,GB 201001159 A,2009-02-02,GB 0801852 A;;GB 0901705 A,2008-02-01,Hanging bar having a pair of bar suspension artifacts and two substrate engagement artifacts for supporting a substrate,"A hanging bar is disclosed which comprises an elongate, stabiliser bar 20 which incorporates as integral parts of the bar a pair of mutually spaced bar suspension artifacts 26,28 (e.g. dome-shaped deformations), and two substrate engagement artifacts (21, Fig.1) (e.g. hooks) mutually spaced longitudinally of the stabiliser bar and integral therewith, wherein the substrate engagement hooks engage with apertures 18,19 in a substrate 12. Alternatively, in another arrangement (Fig.6) the substrate has a fixed first distance between its said apertures, and the hanging aid comprises an elongate, stabiliser bar (222) with a modulus of elasticity permitting it to be manually bowed, at least one suspension artifact (226) for use in supporting the bar, and two substrate engagement artifacts 223,224 (e.g. hooks) mutually spaced longitudinally of the unstressed bar by a fixed second distance that is marginally greater than the said fixed first distance between the substrate's said apertures. The stabilizer bar is arcuately bendable manually to permit engagement of the engagement hooks into the substrate apertures and, upon release, to engage resiliently the substrate without tearing the apertures.",AUGUSTUS MARTIN LTD,BARROW LASCELLE;;PATTISON DANIEL;;STOKES GLYNN;;SNEDDON STUART,,https://lens.org/198-041-767-873-440,Patent Application,no,4,0,3,7,0,G09F7/18;;G09F7/18;;G09F2007/186,G09F7/18,,0,0,,,,INACTIVE
62,WO,A1,WO 2012/104317 A1,168-201-716-486-020,2012-08-09,2012,EP 2012051598 W,2012-01-31,GB 201101796 A,2011-02-02,HANGERS FOR DISPLAY MATERIAL,"A hanger for hanging a substrate (3) bearing indicia (4). An elongate stabiliser bar (1) incorporates a pair of mutually spaced bar suspension artifacts (7, 9) each for suspension by a filament or rod (10), and two hook-like substrate engagement artifacts (6), mutually spaced longitudinally of the stabiliser bar to engage with apertures (5) in the substrate (3). At least one elongate member (2) is provided for connecting the bar (1) to one of said filaments or rods (10), the elongate member extending from a point (8) on the bar spaced from the suspension artifact (7) for suspension by the respective filament or rod.",AUGUSTUS MARTIN LTD;;PATTISON DANIEL;;ASLET PETER;;STOKES GLYN;;BARROW LASCELLE,PATTISON DANIEL;;ASLET PETER;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/168-201-716-486-020,Patent Application,yes,3,0,7,7,0,G09F7/18;;G09F2007/186;;G09F7/18;;G09F2007/186,G09F7/18,,0,0,,,,PENDING
63,GB,A,GB 2477144 A,180-514-222-453-263,2011-07-27,2011,GB 201001145 A,2010-01-25,GB 201001145 A,2010-01-25,Locking tabs for selvedge of hanging display material,"A printed sheet 10 for forming a hanging display, comprises an upper selvedge 12 bounded by an edge of the sheet and at least one score line 12a. One or more tabs 13 and a corresponding number of tab-receiving slots 18 are provided in or adjacent to the selvedge 12 or score line 12a. The tabs have a leading portion 15 which is insertable into the slots and which is provided with locking wings 15a, 15b which are bent over to lock the leading portion in the slot. The selvedge 12 enhances the rigidity of the sheet and apertures 16 in the protruding tabs allow hanging of the sheet 10. The leading portion 15 of the tabs is of tapering form, with a trailing end defined by lateral slits 17 extending inwardly from side edges to define the locking wings.",AUGUSTUS MARTIN LTD,BARROW LASCELLE;;PATTISON DANIEL;;STOKES GLYNN;;SNEDDON STUART,,https://lens.org/180-514-222-453-263,Patent Application,no,7,0,3,3,0,G09F1/04;;G09F1/10;;G09F7/18;;G09F1/10;;G09F1/04;;G09F3/08;;G09F7/18;;G09F2007/186,G09F1/04;;G09F1/10;;G09F7/18,,0,0,,,,INACTIVE
64,ES,T3,ES 2538389 T3,126-484-719-934-65X,2015-06-19,2015,ES 12703045 T,2012-01-31,GB 201101796 A;;EP 2012051598 W,2011-02-02,Colgadores para material de presentación,"Un colgador para colgar un substrato (3) portador de indicaciones, comprendiendo el colgador una barra estabilizadora (1, 101) alargada que incorpora, como partes integrales de la barra: un par de objetos (7, 9) de suspensión de barra mutuamente separados, cada uno de ellos para su suspensión por medio de un filamento o una varilla (10), y dos objetos (6, 106) de enganche del substrato, mutuamente separados en la dirección longitudinal de la barra estabilizadora (1, 101), siendo los objetos de enganche del substrato en forma de gancho para encajar con aberturas (5) del substrato (3), caracterizado porque el colgador incluye al menos un miembro (2, 2', 102) alargado para conectar la barra a uno de dichos filamentos o varillas (10), extendiéndose el miembro alargado desde un punto (8) de la barra (1, 101) distanciado del objeto (7, 9) de suspensión para su suspensión por medio del filamento o la varilla respectivos.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;ASLET PETER;;STOKES GLYN;;BARROW LASCELLE,,https://lens.org/126-484-719-934-65X,Granted Patent,no,0,0,7,7,0,G09F7/18;;G09F2007/186;;G09F7/18;;G09F2007/186,G09F7/18,,0,0,,,,ACTIVE
65,US,A1,US 2023/0310368 A1,133-502-753-097-621,2023-10-05,2023,US 202318331682 A,2023-06-08,US 202318331682 A;;US 202318186764 A;;US 202217734100 A;;US 202163184703 P,2021-05-05,MDMA ENANTIOMERS,"A composition for use in psychotherapeutic or medical treatment of an R(−) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(−) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA.",MIND MEDICINE INC,BARROW ROBERT;;KARLIN DANIEL R;;SMAGIN GENNADY N,MIND MEDICINE INC (2023-06-30),https://lens.org/133-502-753-097-621,Patent Application,yes,0,0,1,10,0,A61K31/198;;A61K31/36;;A61P25/22;;A61P25/28;;A61K9/0043;;A61K9/0019;;A61K31/36;;A61P25/28;;A61P25/22;;A61K47/542,A61K31/36;;A61K47/54;;A61P25/22;;A61P25/28,,0,0,,,,PENDING
66,GB,B,GB 2486217 B,008-084-288-660-552,2012-11-14,2012,GB 201020650 A,2010-12-07,GB 201020650 A,2010-12-07,Posters,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;BARROW LASCELLE AUGUSTUS;;ASLET PETER;;STOKES GLYNN,,https://lens.org/008-084-288-660-552,Granted Patent,no,2,0,3,3,0,G09F15/0018;;G09F15/02;;G09F15/00;;G09F15/02,G09F15/02;;G09F15/00,,0,0,,,,INACTIVE
67,GB,A,GB 2487746 A,123-484-730-106-151,2012-08-08,2012,GB 201101796 A,2011-02-02,GB 201101796 A,2011-02-02,Hanger for hanging display material.,"A hanger for hanging a substrate 3 bearing indicia 4 comprises an elongate stabiliser bar 1 which incorporates a pair of mutually spaced bar suspension elements 7, 9 each for suspension by a filament or rod 10, and two hook-like substrate engagement elements (6, Fig. 2), spaced longitudinally on the stabiliser bar to engage apertures 5 in the substrate. At least one elongate member 2 is provided for connecting the bar 1 to one of said filaments or rods 10, the elongate member extending from a point 8 on the bar spaced from the respective. The stabiliser bar is preferably flexible so that it is bowed when the substrate is hung from it to impart tension to and rigidify the substrate.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;ASLET PETER;;STOKES GLYNN;;BARROW LASCELLE AUGUSTUS,,https://lens.org/123-484-730-106-151,Patent Application,no,2,0,7,7,0,G09F7/18;;G09F2007/186;;G09F7/18;;G09F2007/186,G09F7/18,,0,0,,,,INACTIVE
68,WO,A1,WO 2023/278131 A1,091-179-956-907-605,2023-01-05,2023,US 2022/0033308 W,2022-06-13,US 202163216683 P,2021-06-30,SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION,"A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device.",MIND MEDICINE INC,MAJERNIK MARTIN;;KARLIN DANIEL R;;BARROW ROBERT;;DUBEC PETER,,https://lens.org/091-179-956-907-605,Patent Application,yes,5,0,7,7,0,A61B5/4848;;A61B5/6802;;A61B5/681;;A61B5/0205;;A61B5/021;;A61B5/024;;A61B5/1104;;A61B5/165;;A61B5/0022;;G16H20/10;;A61B2562/0219;;A61B2562/0204;;A61B5/0077;;G16H20/70;;G16H50/20;;G16H40/67;;A61B5/4848;;A61B2562/0204;;A61B5/024;;A61B5/1104;;G16H40/67;;A61B5/165;;G16H50/20;;A61B5/0004;;A61B5/4803;;A61B5/1118;;G16H20/70;;A61B5/021;;A61B5/0205;;A61B2562/0219;;A61B5/0022;;A61B5/6802;;G16H20/10;;A61B5/74;;A61B5/681;;A61B5/1113;;A61B5/0077;;A61B5/6898;;A61B5/4848;;A61B5/681;;A61B5/4803;;A61B5/1113;;A61B5/0205;;A61B5/165;;A61B5/024;;A61B5/6898;;A61B5/74;;A61B2562/0204;;A61B2562/0219;;A61B5/021;;A61B5/1118;;A61B5/0004,A61B5/00,,0,0,,,,PENDING
69,US,A,US 2480829 A,070-895-118-735-846,1949-09-06,1949,US 42869842 A,1942-01-29,US 42869842 A,1942-01-29,Radio direction indicating apparatus,,RESEARCH CORP,BARROW WILMER L;;PENSYL DANIEL S;;MIEHER WALTER W,,https://lens.org/070-895-118-735-846,Granted Patent,no,22,39,2,2,0,G01S13/68;;G01S13/68;;G01S1/02;;G01S1/02,G01S1/02;;G01S13/68;;G01S19/28;;G01S19/35,,0,0,,,,EXPIRED
70,US,A1,US 2023/0000431 A1,092-072-857-409-498,2023-01-05,2023,US 202217839374 A,2022-06-13,US 202217839374 A;;US 202163216683 P,2021-06-30,SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION,"A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device.",MIND MEDICINE INC,MAJERNIK MARTIN;;KARLIN DANIEL R;;BARROW ROBERT;;DUBEC PETER,MIND MEDICINE INC (2021-07-12),https://lens.org/092-072-857-409-498,Patent Application,yes,0,0,7,7,0,A61B5/4848;;A61B5/6802;;A61B5/681;;A61B5/0205;;A61B5/021;;A61B5/024;;A61B5/1104;;A61B5/165;;A61B5/0022;;G16H20/10;;A61B2562/0219;;A61B2562/0204;;A61B5/0077;;G16H20/70;;G16H50/20;;G16H40/67;;A61B5/4848;;A61B2562/0204;;A61B5/024;;A61B5/1104;;G16H40/67;;A61B5/165;;G16H50/20;;A61B5/0004;;A61B5/4803;;A61B5/1118;;G16H20/70;;A61B5/021;;A61B5/0205;;A61B2562/0219;;A61B5/0022;;A61B5/6802;;G16H20/10;;A61B5/74;;A61B5/681;;A61B5/1113;;A61B5/0077;;A61B5/6898;;A61B5/4848;;A61B5/681;;A61B5/4803;;A61B5/1113;;A61B5/0205;;A61B5/165;;A61B5/024;;A61B5/6898;;A61B5/74;;A61B2562/0204;;A61B2562/0219;;A61B5/021;;A61B5/1118;;A61B5/0004,A61B5/00;;A61B5/0205;;A61B5/11;;A61B5/16,,0,0,,,,PENDING
71,GB,B,GB 2487746 B,002-238-924-334-67X,2013-05-22,2013,GB 201101796 A,2011-02-02,GB 201101796 A,2011-02-02,Hangers for display material,,AUGUSTUS MARTIN LTD,PATTISON DANIEL;;ASLET PETER;;STOKES GLYNN;;BARROW LASCELLE AUGUSTUS,,https://lens.org/002-238-924-334-67X,Granted Patent,no,2,0,7,7,0,G09F7/18;;G09F2007/186;;G09F7/18;;G09F2007/186,G09F7/18,,0,0,,,,INACTIVE
72,DE,D1,DE 602005000664 D1,182-795-672-646-755,2007-04-19,2007,DE 602005000664 T,2005-06-06,GB 0416567 A;;GB 0419306 A,2004-07-24,Abhängeanzeigevorrichtungen,"An arrangement for hanging printed sheet material for display in which the sheet is printed on at least a front face; has an upper selvedge bounded by an edge of the sheet and at least one score line; said edge is contoured to define one or more tabs; a corresponding number of tab-receiving slots are provided in or adjacent to the selvedge or said score line, and an aperture is provided in the or each tab such that, with the upper selvedge folded over and the or each tab inserted into the or each associated tab-receiving slot to protrude upwardly therefrom. The upper selvedge enhances the rigidity of the sheet and the aperture or apertures in the protruding tab or tabs provide means for use in hanging the sheet.",AUGUSTUS MARTIN LTD,BARROW LASCELLES;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/182-795-672-646-755,Granted Patent,no,0,0,8,15,0,G09F1/103,G09F1/10;;G09F17/00,,0,0,,,,INACTIVE
73,IL,A,IL 309297 A,000-502-254-111-836,2024-02-01,2024,IL 30929723 A,2023-12-11,US 202163216683 P;;US 2022/0033308 W,2021-06-30,System and method for monitoring a consciousness-altering therapeutic session,,MIND MEDICINE INC;;MAJERNIK MARTIN;;KARLIN DANIEL R;;BARROW ROBERT;;DUBEC PETER,MAJERNIK MARTIN;;KARLIN DANIEL R;;BARROW ROBERT;;DUBEC PETER,,https://lens.org/000-502-254-111-836,Patent Application,no,0,0,7,7,0,A61B5/4848;;A61B5/6802;;A61B5/681;;A61B5/0205;;A61B5/021;;A61B5/024;;A61B5/1104;;A61B5/165;;A61B5/0022;;G16H20/10;;A61B2562/0219;;A61B2562/0204;;A61B5/0077;;G16H20/70;;G16H50/20;;G16H40/67;;A61B5/4848;;A61B2562/0204;;A61B5/024;;A61B5/1104;;G16H40/67;;A61B5/165;;G16H50/20;;A61B5/0004;;A61B5/4803;;A61B5/1118;;G16H20/70;;A61B5/021;;A61B5/0205;;A61B2562/0219;;A61B5/0022;;A61B5/6802;;G16H20/10;;A61B5/74;;A61B5/681;;A61B5/1113;;A61B5/0077;;A61B5/6898;;A61B5/4848;;A61B5/681;;A61B5/4803;;A61B5/1113;;A61B5/0205;;A61B5/165;;A61B5/024;;A61B5/6898;;A61B5/74;;A61B2562/0204;;A61B2562/0219;;A61B5/021;;A61B5/1118;;A61B5/0004,G16H20/10;;G16H20/70;;G16H40/67;;G16H50/20,,0,0,,,,PENDING
74,TW,A,TW 202315573 A,017-052-358-649-608,2023-04-16,2023,TW 111122825 A,2022-06-20,US 202163216683 P,2021-06-30,System and method for monitoring a consciousness-altering therapeutic session,"A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device.",MIND MEDICINE INC,MAJERNIK MARTIN;;KARLIN DANIEL R;;BARROW ROBERT;;DUBEC PETER,,https://lens.org/017-052-358-649-608,Patent of Addition,no,0,0,7,7,0,A61B5/4848;;A61B5/6802;;A61B5/681;;A61B5/0205;;A61B5/021;;A61B5/024;;A61B5/1104;;A61B5/165;;A61B5/0022;;G16H20/10;;A61B2562/0219;;A61B2562/0204;;A61B5/0077;;G16H20/70;;G16H50/20;;G16H40/67;;A61B5/4848;;A61B2562/0204;;A61B5/024;;A61B5/1104;;G16H40/67;;A61B5/165;;G16H50/20;;A61B5/0004;;A61B5/4803;;A61B5/1118;;G16H20/70;;A61B5/021;;A61B5/0205;;A61B2562/0219;;A61B5/0022;;A61B5/6802;;G16H20/10;;A61B5/74;;A61B5/681;;A61B5/1113;;A61B5/0077;;A61B5/6898;;A61B5/4848;;A61B5/681;;A61B5/4803;;A61B5/1113;;A61B5/0205;;A61B5/165;;A61B5/024;;A61B5/6898;;A61B5/74;;A61B2562/0204;;A61B2562/0219;;A61B5/021;;A61B5/1118;;A61B5/0004,A61B5/00;;A61B5/0205;;A61B5/11;;A61B5/16,,0,0,,,,PENDING
75,GB,A,GB 2486217 A,097-793-324-587-146,2012-06-13,2012,GB 201020650 A,2010-12-07,GB 201020650 A,2010-12-07,Sectional poster mounting alignment system.,"A poster mounting alignment system comprises an alignment element 1 which is provided with a plurality of lugs 10-18, and a poster which is provided in a plurality of sections 20-23, each of which has a plurality of openings 30-38 adjacent an edge of the poster. The opening co-operate with the lugs to achieve the correct alignment of the poster in a viewing position by placing at least some of the openings around at least some of the lugs. The configurations of the lugs and the holes may be different between different sections so that each section of the poster can only fit in its intended position. The lugs and holes may be provided in circular and elongate forms and the spacing between them may be altered to create the different configurations. A clip may be provided for holding the poster sections on the alignment element.",AUGUSTUS MARTIN LTD,PATTISON DANIEL;;BARROW LASCELLE AUGUSTUS;;ASLET PETER;;STOKES GLYNN,,https://lens.org/097-793-324-587-146,Patent Application,no,2,0,3,3,0,G09F15/0018;;G09F15/02;;G09F15/00;;G09F15/02,G09F15/02;;G09F15/00,,0,0,,,,INACTIVE
76,AU,A1,AU 2022/304545 A1,115-197-899-510-73X,2024-01-04,2024,AU 2022/304545 A,2022-06-13,US 202163216683 P;;US 2022/0033308 W,2021-06-30,SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION,"A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device.",MIND MEDICINE INC,MAJERNIK MARTIN;;KARLIN DANIEL R;;BARROW ROBERT;;DUBEC PETER,,https://lens.org/115-197-899-510-73X,Patent Application,no,0,0,7,7,0,A61B5/4848;;A61B5/6802;;A61B5/681;;A61B5/0205;;A61B5/021;;A61B5/024;;A61B5/1104;;A61B5/165;;A61B5/0022;;G16H20/10;;A61B2562/0219;;A61B2562/0204;;A61B5/0077;;G16H20/70;;G16H50/20;;G16H40/67;;A61B5/4848;;A61B2562/0204;;A61B5/024;;A61B5/1104;;G16H40/67;;A61B5/165;;G16H50/20;;A61B5/0004;;A61B5/4803;;A61B5/1118;;G16H20/70;;A61B5/021;;A61B5/0205;;A61B2562/0219;;A61B5/0022;;A61B5/6802;;G16H20/10;;A61B5/74;;A61B5/681;;A61B5/1113;;A61B5/0077;;A61B5/6898;;A61B5/4848;;A61B5/681;;A61B5/4803;;A61B5/1113;;A61B5/0205;;A61B5/165;;A61B5/024;;A61B5/6898;;A61B5/74;;A61B2562/0204;;A61B2562/0219;;A61B5/021;;A61B5/1118;;A61B5/0004,A61B5/00,,0,0,,,,PENDING
77,PT,E,PT 1619646 E,146-844-825-025-830,2007-05-31,2007,PT 05104891 T,2005-06-06,GB 0416567 A;;GB 0419306 A,2004-07-24,HANGING DISPLAY ARRANGEMENTS,,AUGUSTUS MARTIN LTD,BARROW LASCELLES;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/146-844-825-025-830,Granted Patent,no,0,0,1,15,0,,G09F1/10;;G09F17/00,,0,0,,,,ACTIVE
78,AT,T1,AT E356396 T1,142-859-683-946-98X,2007-03-15,2007,AT 05104891 T,2005-06-06,GB 0416567 A;;GB 0419306 A,2004-07-24,ABHÄNGEANZEIGEVORRICHTUNGEN,"An arrangement for hanging printed sheet material for display in which the sheet is printed on at least a front face; has an upper selvedge bounded by an edge of the sheet and at least one score line; said edge is contoured to define one or more tabs; a corresponding number of tab-receiving slots are provided in or adjacent to the selvedge or said score line, and an aperture is provided in the or each tab such that, with the upper selvedge folded over and the or each tab inserted into the or each associated tab-receiving slot to protrude upwardly therefrom. The upper selvedge enhances the rigidity of the sheet and the aperture or apertures in the protruding tab or tabs provide means for use in hanging the sheet.",AUGUSTUS MARTIN LTD,BARROW LASCELLES;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/142-859-683-946-98X,Granted Patent,no,0,0,8,15,0,G09F1/103,,,0,0,,,,INACTIVE
79,CA,A1,CA 3224790 A1,133-177-520-924-220,2023-01-05,2023,CA 3224790 A,2022-06-13,US 202163216683 P;;US 2022/0033308 W,2021-06-30,SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION,"A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device.",MIND MEDICINE INC,MAJERNIK MARTIN;;KARLIN DANIEL R;;BARROW ROBERT;;DUBEC PETER,,https://lens.org/133-177-520-924-220,Patent Application,no,0,0,7,7,0,A61B5/4848;;A61B5/6802;;A61B5/681;;A61B5/0205;;A61B5/021;;A61B5/024;;A61B5/1104;;A61B5/165;;A61B5/0022;;G16H20/10;;A61B2562/0219;;A61B2562/0204;;A61B5/0077;;G16H20/70;;G16H50/20;;G16H40/67;;A61B5/4848;;A61B2562/0204;;A61B5/024;;A61B5/1104;;G16H40/67;;A61B5/165;;G16H50/20;;A61B5/0004;;A61B5/4803;;A61B5/1118;;G16H20/70;;A61B5/021;;A61B5/0205;;A61B2562/0219;;A61B5/0022;;A61B5/6802;;G16H20/10;;A61B5/74;;A61B5/681;;A61B5/1113;;A61B5/0077;;A61B5/6898;;A61B5/4848;;A61B5/681;;A61B5/4803;;A61B5/1113;;A61B5/0205;;A61B5/165;;A61B5/024;;A61B5/6898;;A61B5/74;;A61B2562/0204;;A61B2562/0219;;A61B5/021;;A61B5/1118;;A61B5/0004,A61B5/00,,0,0,,,,PENDING
80,DE,T2,DE 602005000664 T2,145-766-759-157-036,2007-11-22,2007,DE 602005000664 T,2005-06-06,GB 0416567 A;;GB 0419306 A,2004-07-24,Abhängeanzeigevorrichtungen,"An arrangement for hanging printed sheet material for display in which the sheet is printed on at least a front face; has an upper selvedge bounded by an edge of the sheet and at least one score line; said edge is contoured to define one or more tabs; a corresponding number of tab-receiving slots are provided in or adjacent to the selvedge or said score line, and an aperture is provided in the or each tab such that, with the upper selvedge folded over and the or each tab inserted into the or each associated tab-receiving slot to protrude upwardly therefrom. The upper selvedge enhances the rigidity of the sheet and the aperture or apertures in the protruding tab or tabs provide means for use in hanging the sheet.",AUGUSTUS MARTIN LTD,BARROW LASCELLES;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/145-766-759-157-036,Granted Patent,no,0,0,8,15,0,G09F1/103,G09F1/10;;G09F17/00,,0,0,,,,INACTIVE
81,EP,B1,EP 3250209 B1,007-408-306-713-649,2023-09-13,2023,EP 16744242 A,2016-01-29,US 201562109954 P;;US 2016/0015832 W,2015-01-30,COMT INHIBITING METHODS AND COMPOSITIONS,,LIEBER INST FOR BRAIN DEVELOPMENT,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID;;WEINBERGER DANIEL,,https://lens.org/007-408-306-713-649,Granted Patent,yes,0,0,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,A61K31/535;;A61K31/198;;A61K31/47;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/5377;;A61K31/55;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;C07D215/36;;C07D401/12;;C07D401/14;;C07D417/12;;C07D471/04,,10,1,000-505-287-507-099,pmc6256987;;20110891;;10.3390/molecules15010288,"MAKHLOUF M TH; ABDEL-HAFEZ A A; IBRAHIM S A: ""EFFECT OF CHELATING 8 - HYDROXYQUINOLIN DERIVATIVES ON THE CORROSION OF ZINC IN POLYBASIC ACIDS"", JOURNAL OF THE ELECTROCHEMICAL SOCIETY OF INDIA, vol. 35, no. 2, April 1986 (1986-04-01), pages 89 - 92, XP009540030, ISSN: 0013-466X;;MUSIOL ROBERT ET AL: ""Investigating the Activity Spectrum for Ring-Substituted 8-Hydroxyquinolines"", MOLECULES, vol. 15, no. 1, 12 January 2010 (2010-01-12), pages 288 - 304, XP055973728, DOI: 10.3390/molecules15010288;;DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 November 1984 (1984-11-16), XP055973753, accession no. 61430-90-8 Database accession no. 61430-90-8;;DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 November 1984 (1984-11-16), XP055973756, accession no. 61430-95-3 Database accession no. 61430-95-3;;DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 July 1987 (1987-07-03), XP055973757, accession no. 109024-19-3 Database accession no. 109024-19-3;;DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 14 January 1993 (1993-01-14), XP055973759, accession no. 145327-16-8 Database accession no. 145327-16-8;;ANONIMOUS: ""RN -61430-90-8 REGISTRY ED -Entered STN: 16 Nov 1984 CN -8-Quinolinol, 5-(phenylsulfonyl)- (CA INDEX NAME) OTHER CA INDEX NAMES: CN"", 16 November 1994 (1994-11-16), pages 1 - 1, XP055973753, Retrieved from the Internet <URL:stn.org> [retrieved on 20221021];;ANONIMOUS: ""61439-95-3"", 16 November 1984 (1984-11-16), pages 1 - 1, XP055973756, Retrieved from the Internet <URL:stn.org> [retrieved on 20221021];;ANONIMOUS: ""109024-19-3"", 3 July 1987 (1987-07-03), pages 1 - 1, XP055973757, Retrieved from the Internet <URL:stn.org> [retrieved on 20221021];;ANONIMOUS: ""145327-16-8"", 14 January 1993 (1993-01-14), pages 1 - 1, XP055973759, Retrieved from the Internet <URL:stn.org> [retrieved on 20221021]",ACTIVE
82,EP,B1,EP 1619646 B1,093-863-944-635-810,2007-03-07,2007,EP 05104891 A,2005-06-06,GB 0416567 A;;GB 0419306 A,2004-07-24,Hanging display arrangements,"An arrangement for hanging printed sheet material for display in which the sheet is printed on at least a front face; has an upper selvedge bounded by an edge of the sheet and at least one score line; said edge is contoured to define one or more tabs; a corresponding number of tab-receiving slots are provided in or adjacent to the selvedge or said score line, and an aperture is provided in the or each tab such that, with the upper selvedge folded over and the or each tab inserted into the or each associated tab-receiving slot to protrude upwardly therefrom. The upper selvedge enhances the rigidity of the sheet and the aperture or apertures in the protruding tab or tabs provide means for use in hanging the sheet.",AUGUSTUS MARTIN LTD,BARROW LASCELLES AUGUSTUS;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/093-863-944-635-810,Granted Patent,yes,3,0,8,15,0,G09F1/103,G09F1/10;;G09F17/00,,0,0,,,,ACTIVE
83,US,A1,US 2010/0315218 A1,091-233-278-224-69X,2010-12-16,2010,US 75827310 A,2010-04-12,US 75827310 A;;US 18652709 P,2009-06-12,Inclement Condition Speedometer,"A system for communicating to a motor vehicle operator the maximum safe speed at which the vehicle can be operated. The system includes receiver(s), sensor(s), processor(s) and dashboard display(s). The receiver(s) detects a legal speed limit. Sensor(s) detects environmental conditions surrounding the motor vehicle. The processor(s): receive data from the receiver(s) and sensor(s); calculates a maximum safe speed; and calculates a safe speed range based on the maximum safe speed and the legal speed limit. The dashboard display alerts the driver if the maximum safe speed is less than the legal speed limit, and displays the safe speed range if the maximum safe speed is less than the legal speed limit.",CADES DAVID;;BARROW JANE;;KIDD DAVID;;NELSON ERIK;;ROBERTS DANIEL,CADES DAVID;;BARROW JANE;;KIDD DAVID;;NELSON ERIK;;ROBERTS DANIEL,GEORGE MASON UNIVERSITY (2010-04-22);;GEORGE MASON INTELLECTUAL PROPERTIES INC (2010-08-27),https://lens.org/091-233-278-224-69X,Patent Application,yes,10,80,1,1,0,B60K35/00;;B60W50/14;;B60W2555/60;;B60W2555/20;;B60W2556/50;;B60K35/215;;B60K35/00;;B60W50/14;;B60W2555/20;;B60W2555/60;;B60W2556/50;;B60K35/215,B60Q1/00,340/441,0,0,,,,DISCONTINUED
84,PL,T3,PL 1619646 T3,056-265-599-602-919,2007-07-31,2007,PL 05104891 T,2005-06-06,GB 0416567 A;;GB 0419306 A;;EP 05104891 A,2004-07-24,Hanging display arrangements,"An arrangement for hanging printed sheet material for display in which the sheet is printed on at least a front face; has an upper selvedge bounded by an edge of the sheet and at least one score line; said edge is contoured to define one or more tabs; a corresponding number of tab-receiving slots are provided in or adjacent to the selvedge or said score line, and an aperture is provided in the or each tab such that, with the upper selvedge folded over and the or each tab inserted into the or each associated tab-receiving slot to protrude upwardly therefrom. The upper selvedge enhances the rigidity of the sheet and the aperture or apertures in the protruding tab or tabs provide means for use in hanging the sheet.",AUGUSTUS MARTIN LTD,BARROW LASCELLES AUGUSTUS;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/056-265-599-602-919,Patent Application,no,0,0,8,15,0,G09F1/103,G09F1/10;;G09F17/00,,0,0,,,,PENDING
85,GB,A,GB 2414331 A,128-151-909-454-70X,2005-11-23,2005,GB 0507768 A,2005-04-18,GB 0408912 A;;GB 0416567 A;;GB 0419306 A,2004-04-22,Sign hanging arrangement,"Disclosed is an arrangement for mounting printed sheet material for display, in which the sheet (12) is printed on at least a front face (14). The sheet (12) has an upper selvedge (135) bounded by an edge of the sheet (18) and at least one score line (37). The edge (18) is contoured so as to define one or more tabs (128), and a corresponding number of tab-receiving slots (127) are provided in or adjacent to the selvedge or said score line. An aperture (26) is provided in the, or each, tab (128), and the tab/s (128) are inserted into the, or each, associated tab-receiving (127) slot to protrude upwardly therefrom. The upper selvedge (135) enhances the rigidity of the sheet and the aperture (26), or apertures, in the protruding tabs (128) provide means for use in hanging the sheet (128). The selvedge may consist of four strip-like portions (135a-d) which form a tunnel of triangular cross-section. A flexible element (e.g. a cord) may be passed through the tunnel, providing an alternative means of hanging the sheet (12).",AUGUSTUS MARTIN LTD,BARROW LASCELLES AUGUSTUS;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/128-151-909-454-70X,Patent Application,no,5,4,3,15,0,G09F7/00;;G09F15/02;;G09F15/0012;;G09F1/103;;G09F7/18;;G09F2007/186,G09F1/10;;G09F7/00;;G09F7/18;;G09F15/00;;G09F15/02,G5C CEA           CEA,0,0,,,,INACTIVE
86,WO,A1,WO 2016/123577 A1,071-630-362-476-340,2016-08-04,2016,US 2016/0015833 W,2016-01-29,US 201562109956 P,2015-01-30,COMT INHIBITING METHODS AND COMPOSITIONS,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula (I), or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEV,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID;;WEINBERGER DANIEL,,https://lens.org/071-630-362-476-340,Patent Application,yes,2,2,4,4,0,A61K31/198;;A61K31/198;;A61P25/00;;A61P25/18;;A61P25/28;;A61P25/30;;C07D417/12;;C07D417/12;;C07D215/26;;C07D215/26;;C07D401/12;;C07D401/12;;C07D405/12;;C07D405/12,A61P25/28;;A61K31/47;;C07D215/24,,2,1,042-638-882-922-45X,10.1021/jm00262a016;;4736750,"BORCHARDT: ""Catechol-O-methyltransferase. 2. In Vitro Inhibition by Substituted 8- hydroxyquinolines"", J. MED. CHEM., vol. 16, no. 4, 1973, pages 382 - 387;;DATABASE PUBCHEM 9 February 2007 (2007-02-09), Database accession no. 14508910",PENDING
87,EP,A2,EP 1619646 A2,101-536-864-585-817,2006-01-25,2006,EP 05104891 A,2005-06-06,GB 0416567 A;;GB 0419306 A,2004-07-24,Hanging display arrangements,"An arrangement for hanging printed sheet material for display in which the sheet is printed on at least a front face; has an upper selvedge bounded by an edge of the sheet and at least one score line; said edge is contoured to define one or more tabs; a corresponding number of tab-receiving slots are provided in or adjacent to the selvedge or said score line, and an aperture is provided in the or each tab such that, with the upper selvedge folded over and the or each tab inserted into the or each associated tab-receiving slot to protrude upwardly therefrom. The upper selvedge enhances the rigidity of the sheet and the aperture or apertures in the protruding tab or tabs provide means for use in hanging the sheet.
",AUGUSTUS MARTIN LTD,BARROW LASCELLES AUGUSTUS;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/101-536-864-585-817,Patent Application,yes,0,3,8,15,0,G09F1/103,G09F1/10;;G09F17/00,,0,0,,,,ACTIVE
88,CA,C,CA 2975398 C,114-205-506-037-701,2023-02-21,2023,CA 2975398 A,2016-01-29,US 201562109954 P;;US 2016/0015832 W,2015-01-30,COMT INHIBITING METHODS AND COMPOSITIONS,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEVELOPMENT,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID;;WEINBERGER DANIEL,,https://lens.org/114-205-506-037-701,Granted Patent,no,0,0,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,,,0,0,,,,PENDING
89,WO,A1,WO 2016/123576 A1,042-180-763-614-321,2016-08-04,2016,US 2016/0015832 W,2016-01-29,US 201562109954 P,2015-01-30,COMT INHIBITING METHODS AND COMPOSITIONS,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEV,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID;;WEINBERGER DANIEL,,https://lens.org/042-180-763-614-321,Patent Application,yes,6,4,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,A61K31/535,,21,18,038-065-408-627-840;;017-284-722-565-113;;014-400-652-718-917;;012-886-079-422-020;;024-350-480-021-901;;017-629-356-374-675;;023-879-967-987-269;;078-350-415-030-026;;094-508-681-612-704;;073-549-455-552-730;;064-658-651-136-60X;;069-320-439-367-420;;017-843-787-775-267;;083-133-531-109-460;;083-096-823-966-296;;015-279-435-374-534;;014-883-830-448-77X;;052-555-044-220-642,22342622;;10.1016/j.ab.2012.01.019;;17579498;;10.2165/00023210-200721070-00002;;17894650;;pmc6494163;;10.1111/j.1527-3458.2007.00020.x;;817025;;10.1021/jm00226a025;;pmc6578165;;10.1523/jneurosci.15-03-01714.1995;;7534339;;19223657;;10.1093/schbul/sbn187;;pmc2669580;;10.1007/s00213-004-1793-y;;15118803;;pmc2669582;;19325164;;10.1093/schbul/sbp006;;10.1111/j.1471-4159.2010.06889.x;;20626558;;10.1097/00008571-199606000-00007;;8807664;;21095461;;10.1016/b978-0-12-381326-8.00006-5;;10.1017/s0954579400003138;;11014750;;6367973;;10.1097/00002826-198403000-00002;;10.1002/ana.410180505;;4073849;;17909307;;10.1097/wnf.0b013e318038d2b6;;10.1017/s1462399411001955;;21794196;;10619191;;10.1007/s002109900168;;10.1523/jneurosci.0665-07.2007;;pmc6672678;;17881525,"""Remington: The Science & Practice of Pharmacy"", 2005, WILLIAMS & WILLIAMS;;""Physician's Desk Reference"", 2013, PDR NETWORK;;LIN Y. ET AL.: ""Detecting S-adenosyl-l-methionine-induced conformational change of a histone methyltransferase using a homogeneous time-resolved fluorescence-based binding assay"", ANALYTICAL BIOCHEMISTRY, vol. 423, no. 1, 2012, pages 171 - 177, XP028466654, DOI: 10.1016/j.ab.2012.01.019;;SYNTHESIS, vol. 8, 2006, pages 1325 - 1332;;APUD, J. A.D. R. WEINBERGER: ""Treatment of cognitive deficits associated with schizophrenia - Potential role of catechol-O-methyltransferase inhibitors"", CNS DRUGS, vol. 21, no. 7, 2007, pages 535 - 557;;BONIFACIO, M. J.P. N. PALMA ET AL.: ""Catechol-O-methyltransferase and its inhibitors in Parkinson's disease"", CNS DRUG REVIEWS, vol. 13, no. 3, 2007, pages 352 - 379, XP008154694, DOI: 10.1111/j.1527-3458.2007.00020.x;;BORCHARDT, R. T.D. R. THAKKER ET AL.: ""Catechol O-Methyltransferase .8. Structure-Activity-Relationships for Inhibition by 8-Hydroxyquinolines"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 19, no. 4, 1976, pages 558 - 560;;CILIAX, B. J.C. HEILMAN ET AL.: ""The Dopamine Transporter - Immunochemical Characterization and Localization in Brain"", JOURNAL OF NEUROSCIENCE, vol. 15, no. 3, 1995, pages 1714 - 1723;;FATEMI, S. H.T. D. FOLSOM: ""The Neurodevelopmental Hypothesis of Schizophrenia, Revisited"", SCHIZOPHRENIA BULLETIN, vol. 3 5, no. 3, 2009, pages 528 - 548;;GOLDMAN-RAKIC, P. S.S. A. CASTNER ET AL.: ""Targeting the dopamine D-l receptor in schizophrenia: insights for cognitive dysfunction"", PSYCHOPHARMACOLOGY, vol. 174, no. 1, 2004, pages 3 - 16;;HOWES, O. D.S. KAPUR: ""The Dopamine Hypothesis of Schizophrenia: Version III - The Final Common Pathway"", SCHIZOPHRENIA BULLETIN, vol. 35, no. 3, 2009, pages 549 - 562, XP055361164, DOI: 10.1093/schbul/sbp006;;KAENMAKI, M.A. TAMMIMAKI ET AL.: ""Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice"", JNEUROCHEM, vol. 114, no. 6, 2010, pages 1745 - 1755;;LACHMAN, H. M.D. F. PAPOLOS ET AL.: ""Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders"", PHARMACOGENETICS, vol. 6, no. 3, 1996, pages 243 - 250, XP002066739;;LEARMONTH, D. A.L. E. KISS ET AL.: ""The Chemistry of Catechol O-Methyltransferase Inhibitors"", BASIC ASPECTS OF CATECHOL-O-METHYLTRANSTERASE AND THE CLINICAL APPLICATIONS OF ITS INHIBITORS, vol. 95, 2010, pages 119 - 162;;MARENCO, S.D. R. WEINBERGER: ""The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave"", DEVELOPMENT AND PSYCHOPATHOLOGYL2, no. 3, 2000, pages 501 - 527;;NUTT, J. G.J. H. FELLMAN: ""Pharmacokinetics of Levodopa"", CLINICAL NEUROPHARMACOLOGY, vol. 7, no. 1, 1984, pages 35 - 49;;NUTT, J. G.W. R. WOODWARD ET AL.: ""The Effect of Carbidopa on the Pharmacokinetics of Intravenously Administered Levodopa - the Mechanism of Action in the Treatment of Parkinsonism"", ANNALS OF NEUROLOGY, vol. 18, no. 5, 1985, pages 537 - 543;;OLANOW, C. W.P. B. WATKINS: ""Tolcapone"", CLINICAL NEUROPHARMACOLOGY, vol. 30, no. 5, 2007, pages 287 - 294;;PICKARD, B.: ""Progress in defining the biological causes of schizophrenia"", EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, pages 13;;RUSS, H. ET AL.: ""Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects"", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 360, no. 6, 1999, pages 719 - 720;;YAVICH, L.M. M. FORSBERG ET AL.: ""Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum"", JOURNAL OF NEUROSCIENCE, vol. 27, no. 38, 2007, pages 10196 - 10202",PENDING
90,GB,B,GB 2414331 B,131-048-243-796-342,2006-05-24,2006,GB 0507768 A,2005-04-18,GB 0408912 A;;GB 0416567 A;;GB 0419306 A,2004-04-22,Arrangements for use in displaying printed sheet material,,AUGUSTUS MARTIN LTD,BARROW LASCELLES AUGUSTUS;;PATEL DAKSHESH SHASHIKANT;;PATTISON DANIEL;;STOKES GLYN,,https://lens.org/131-048-243-796-342,Granted Patent,no,5,0,3,15,0,G09F7/00;;G09F15/02;;G09F15/0012;;G09F1/103;;G09F7/18;;G09F2007/186,G09F7/00;;G09F1/10;;G09F7/18;;G09F15/00;;G09F15/02,G5C CEA           CEA,0,0,,,,INACTIVE
91,EP,A4,EP 3250209 A4,003-145-839-284-245,2018-07-04,2018,EP 16744242 A,2016-01-29,US 201562109954 P;;US 2016/0015832 W,2015-01-30,COMT INHIBITING METHODS AND COMPOSITIONS,,LIEBER INST FOR BRAIN DEVELOPMENT,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID;;WEINBERGER DANIEL,,https://lens.org/003-145-839-284-245,Search Report,no,1,0,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,A61K31/198;;A61K31/535;;A61K31/47;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/5377;;A61K31/55;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;C07D215/36;;C07D401/12;;C07D401/14;;C07D417/12;;C07D471/04,,4,4,028-724-570-628-95X;;083-088-149-085-066;;067-168-304-275-215;;146-696-127-349-975,10.1016/j.bmc.2014.06.017;;25002230;;10.1135/cccc19932222;;10.1021/cm035313i;;10.1021/cm9503442,"ARIYASU SHINYA ET AL: ""Design and synthesis of 8-hydroxyquinoline-based radioprotective agents"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 22, no. 15, 18 June 2014 (2014-06-18), pages 3891 - 3905, XP029009849, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2014.06.017;;ALI A. ABDEL HAFEZ: ""Synthesis of some heterocyclic sulfones related to quinolinol"", COLLECT. CZECH. CHEM. COMMUN., vol. 58, 1993, XP002776712;;JUNG-AN CHENG ET AL: ""Solution-processible small molecular organic light-emitting diode material and devices based on the substituted aluminium quinolate"", CHEM MATER, vol. 16, no. 15, 2004, XP002776713;;HOPKINS T A ET AL: ""Substituted aluminum and zinc quinolates with blue-shifted absorbance/luminescence bands: synthesis and spectroscopic, photoluminescence, and electroluminescence characterization"", CHEMISTRY OF MATERIALS, AMERICAN CHEMICAL SOCIETY, vol. 8, no. 2, 1 January 1996 (1996-01-01), pages 344 - 351, XP002309620, ISSN: 0897-4756",ACTIVE
92,CA,A1,CA 2975401 A1,014-371-383-822-360,2016-08-04,2016,CA 2975401 A,2016-01-29,US 201562109956 P;;US 2016/0015833 W,2015-01-30,COMT INHIBITING METHODS AND COMPOSITIONS,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula (I), or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEV,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID;;WEINBERGER DANIEL,,https://lens.org/014-371-383-822-360,Patent Application,no,0,0,4,4,0,A61K31/198;;A61K31/198;;A61P25/00;;A61P25/18;;A61P25/28;;A61P25/30;;C07D417/12;;C07D417/12;;C07D215/26;;C07D215/26;;C07D401/12;;C07D401/12;;C07D405/12;;C07D405/12,A61K31/47;;A61P25/28,,0,0,,,,DISCONTINUED
93,EP,A1,EP 3250209 A1,171-511-742-591-192,2017-12-06,2017,EP 16744242 A,2016-01-29,US 201562109954 P;;US 2016/0015832 W,2015-01-30,COMT INHIBITING METHODS AND COMPOSITIONS,,LIEBER INST FOR BRAIN DEV,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID;;WEINBERGER DANIEL,,https://lens.org/171-511-742-591-192,Patent Application,yes,0,0,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,A61K31/535,,0,0,,,,ACTIVE
94,CA,A1,CA 2975398 A1,107-604-635-257-836,2016-08-04,2016,CA 2975398 A,2016-01-29,US 201562109954 P;;US 2016/0015832 W,2015-01-30,COMT INHIBITING METHODS AND COMPOSITIONS,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEVELOPMENT,BUCHLER INGRID;;BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;WEINBERGER DANIEL,,https://lens.org/107-604-635-257-836,Patent Application,no,0,0,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,,,0,0,,,,PENDING
95,US,B2,US 9951057 B2,077-029-783-217-807,2018-04-24,2018,US 201615011365 A,2016-01-29,US 201615011365 A;;US 201562109956 P,2015-01-30,COMT inhibiting methods and compositions,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEVELOPMENT,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID PRICE;;WEINBERGER DANIEL,LIEBER INSTITUTE INC (2016-05-26),https://lens.org/077-029-783-217-807,Granted Patent,yes,4,0,4,4,0,A61K31/198;;A61K31/198;;A61P25/00;;A61P25/18;;A61P25/28;;A61P25/30;;C07D417/12;;C07D417/12;;C07D215/26;;C07D215/26;;C07D401/12;;C07D401/12;;C07D405/12;;C07D405/12,A61K31/47;;A61K31/198;;C07D215/26;;C07D401/12;;C07D405/12;;C07D417/12,,8,5,042-638-882-922-45X;;028-724-570-628-95X;;067-168-304-275-215;;083-088-149-085-066;;146-696-127-349-975,10.1021/jm00262a016;;4736750;;10.1016/j.bmc.2014.06.017;;25002230;;10.1021/cm035313i;;10.1135/cccc19932222;;10.1021/cm9503442,"Borchardt, “Catechol-O-Methyltransferase, 2, In Vitro Inhibition by Substituted 8-Hydroxyquinolines,” J. Med. Chem., 16(4), pp. 382-387, 1973.;;Pubchem-CID 14508910, Feb. 9, 2007, 10 pages.;;Lieber Institute for Brain Development, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for PCT/US16/15833, dated Apr. 22, 2016, 7 pages.;;Ariyasu et al., “Design and Synthesis of 8-hrydroxyquinoline-based Radioprotective Agents,” Bioorganic & Medicinal Chemistry, vol. 22, No. 15, pp. 3891-3905, 2014.;;Cheng et al., “Solution-processible Small Molecular Organic Light-Emitting Diode Material and Devices based on the Substituted Aluminum Quinolate,” Chem. Mater., vol. 16, No. 15, pp. 2862-2868, 2004.;;Hafez et al., “Synthesis of Some Heterocyclic Sulfones Related to Quinolinol,” Collect. Czech. Chem. Commun., vol. 58, pp. 2222-2226, 1993.;;Hopkins et al., “Substituted Aluminum and Zinc Quinolates with Blue-Shifted Absorbance/luminescence Bands: Synthesis and Spectroscopic, Photoluminescence, and Electroluminescence Characterization,” Chemistry of Materials, vol. 8, No. 2, pp. 344-351, 1996.;;Lieber Institute for Brain Development, Supplementary European Search Report for EP 16744242.5, 8 pages, Jan. 8, 2018.",ACTIVE
96,US,B2,US 10479790 B2,015-324-139-253-711,2019-11-19,2019,US 201816018496 A,2018-06-26,US 201816018496 A;;US 201615011353 A;;US 201562109954 P,2015-01-30,COMT inhibiting methods and compositions,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEVELOPMENT,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID PRICE;;WEINBERGER DANIEL,LIEBER INSTITUTE INC (2016-05-24),https://lens.org/015-324-139-253-711,Granted Patent,yes,11,0,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,A61K31/555;;A61K31/198;;A61K31/47;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/5377;;A61K31/55;;A61K45/06;;C07D215/36;;C07D401/12;;C07D401/14;;C07D417/12;;C07D471/04;;C07D471/10,,21,13,028-724-570-628-95X;;067-168-304-275-215;;024-573-559-164-700;;073-142-614-942-038;;052-852-123-441-188;;083-088-149-085-066;;156-960-155-177-181;;146-696-127-349-975;;013-686-033-804-234;;000-505-287-507-099;;074-688-381-260-853;;045-969-062-273-373;;042-638-882-922-45X,10.1016/j.bmc.2014.06.017;;25002230;;10.1021/cm035313i;;10.2174/22113626130104;;23247256;;10.1016/j.bioorg.2012.10.003;;10.1002/jctb.280550202;;10.1135/cccc19932222;;10.1080/10426509108036821;;10.1021/cm9503442;;22870804;;10.1007/s12272-012-0602-0;;pmc6256987;;20110891;;10.3390/molecules15010288;;14361901;;10.4269/ajtmh.1955.4.224;;25815153;;pmc4360154;;10.1021/ml500502d;;10.1021/jm00262a016;;4736750,"Ariyasu et al., “Design and Synthesis of 8-hrydroxyquinoline-based Radioprotective Agents,” Bioorganic & Medicinal Chemistry, vol. 22, No. 15, pp. 3891-3905, 2014.;;Cheng et al., “Solution-processible Small Molecular Organic Light-Emitting Diode Material and Devices based on the Substituted Aluminum Quinolate,” Chem. Mater., vol. 16, No. 15, pp. 2862-2868, 2004.;;Eweas et al, Synthesis, antischstosomal activity and molecular modeling of two novel 8-hydroxyquinoline derivatives, Anti-Infective Agents, 2013, 11(1), p. 3140, an abstract page (Year: 2013).;;Eweas et al, Design, synthesis, anti-schistosomal activity and molecualr docking of novel 8-hydroxyquinoline-5-sulfonyl 1,4-diazepine derivatives, Bioorganic Chemistry, 2013, 46, p. 17-25.;;Hafez et al, Synthesis and biological activity of some new 8-hydroxyquinoline sulfonamide derivatives, Phosphorus, Sulfur and the Related Elements, 1988, 40(3-4), p. 219-225 ,an abstract page (Year: 1988).;;Hafez et al , Nitriles in heterocyclic synthesis. Part II. synthesis and application of pyrano[3,2-h]quinoline sulfonamide derivatives, Journal of Chemical Technology and Biotechnology, 1992, 55(2), p. 95-101 ,an abstract page (Year: 1992).;;Hafez et al., “Synthesis of Some Heterocyclic Sulfones Related to Quinolinol,” Collect. Czech. Chem. Commun., vol. 58, pp. 2222-2226, 1993.;;Hafez et al, Synthesis and application of some new 5-sulfonyl-N-heterocyclyl-8-hydroxyquinoline derivatvies as potential drugs, Phosphorus, Sulfur and Silicon and the Related Elements, 1991, 61 (3-4), p. 381-9, abstract (2 pages).;;Hopkins et al., “Substituted Aluminum and Zinc Quinolates with Blue-Shifted Absorbance/luminescence Bands: Synthesis and Spectroscopic, Photoluminescence, and Electroluminescence Characterization,” Chemistry of Materials, vol. 8, No. 2, pp. 344-351, 1996.;;Kassem et al, Synthesis, antimicrobial , and antiviral activities of some new 5-sulphonamido-8-hydroquinoline derivatives, Archives of Pharmacal Research, 2012, 35(6), p. 955-964. (Year: 2012).;;Kassem et al, Synthesis of some new derivatives of 8-hydroxyquinoline of possible biological activity, Bulletin of the National Research Centre (Egypt),1997, 22(1), p. 97-106, an abstract page (Year: 1997).;;Lieber Institute for Brain Development, Supplementary European Search Report for EP 16744242.5, 8 pages, dated Jan. 8, 2018.;;Lieber Institute for Brain Development, Notification of Transmittal of the International Search Report and the Written Opinion of the International Search Authority, or the Declaration for PCT/US16/15832, 12 pages, dated Apr. 11, 2016.;;Makhlouf et al , Effect of chelating 8-hydroxyquinoline derivatives on the corrosion of zinc in polybasic acids, Journal of the Electrochemical Society of India, 1986,35(2), p. 89-92, an abstract page (Year: 1986).;;Musiol et al, Investigating the activity spectrum for ring-substituted 8-hydroxyquinolines, Molecules , 2010, 15, p. 288-304, an abstract page (Year: 2010).;;Patwa et al, Fries reaction. Part XIII: Preparation of 5- or 7-arylsulfonyl 8-hydroxyquinoline, Journal of the Institution of Chemists (india), 1976, 48, pt. 3, p. 116-18, abstract (1 page).;;Tewari et al, 8-hydroxyquinolino-5-(p-tolyl)sulfonamide as a new gravimetric reagent for chromium (III), Science and Culture, 1980, 46(10), p. 357-358, an abstract page. (Year: 1980).;;Thompson et al, 5- chloro-7-diethylaminomethyl-8-quinolinol and of other substituted 8-quinolinols in vitro and in experimental animals, American Journal of Tropical Medicine and hygiene, 1955, 4, p. 224-248. (Year: 1955).;;Harrison et al., “Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase {COMT)”, ACS Medicinal Chemistry Letters, Jan. 26, 2015, pp. 318-323, vol. 6. No. 3.;;Borchardt, “Catechol-O-methyltransferase 2. In Vitro Inhibition by Substituted 8-hydroxyquinolines”, J Med. Chem., 1973, pp. 382-387, vol. 16 (4).;;Pubchem-cid 145508910 Create date: Feb. 9, 2007, p. 3.",ACTIVE
97,US,A1,US 2018/0305360 A1,016-239-696-583-297,2018-10-25,2018,US 201816018496 A,2018-06-26,US 201816018496 A;;US 201615011353 A;;US 201562109954 P,2015-01-30,COMT Inhibiting Methods and Compositions,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEVELOPMENT,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID PRICE;;WEINBERGER DANIEL,LIEBER INSTITUTE INC (2016-05-24),https://lens.org/016-239-696-583-297,Patent Application,yes,1,0,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,C07D471/10;;A61K31/198;;A61K31/47;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/5377;;A61K31/55;;A61K45/06;;C07D215/36;;C07D401/12;;C07D401/14;;C07D417/12;;C07D471/04,,0,0,,,,ACTIVE
98,US,A1,US 2016/0222011 A1,017-282-434-072-753,2016-08-04,2016,US 201615011353 A,2016-01-29,US 201615011353 A;;US 201562109954 P,2015-01-30,COMT Inhibiting Methods and Compositions,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEV,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID PRICE;;WEINBERGER DANIEL,LIEBER INSTITUTE INC (2016-05-24),https://lens.org/017-282-434-072-753,Patent Application,yes,0,2,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,C07D471/10;;A61K31/198;;A61K31/47;;A61K31/4709;;A61K31/496;;A61K31/5377;;A61K31/55;;C07D215/36;;C07D401/12;;C07D401/14;;C07D417/12;;C07D471/04,,3,2,073-142-614-942-038;;156-960-155-177-181,23247256;;10.1016/j.bioorg.2012.10.003;;10.1080/10426509108036821,"Eweas et al, Design, synthesis, anti-schistosomal activity and molecualr docking of novel 8-hydroxyquinoline-5-sulfonyl 1,4-diazepine derivatives ,Bioorganic Chemistry, 2013, 46, p.17-25.;;Patwa et al, Fries reaction. Part XIII: Preparation of 5- or 7-arylsulfonyl 8-hydroxyquinoline, Journal of the Institution of Chemists (india), 1976, 48, pt. 3, p.116-18, a copy of abstract (1 page).;;Hafez et al, Synthesis and application of some new 5-sulfonyl-N-heterocyclyl-8-hydroxyquinoline derivatvies as potential drugs, Phosphorus, Sulfur and Silicon and the Related Elements, 1991, 61(3-4), p.381-9, a copy of abstract (2 pages).",ACTIVE
99,US,B2,US 10035799 B2,186-771-841-764-568,2018-07-31,2018,US 201615011353 A,2016-01-29,US 201615011353 A;;US 201562109954 P,2015-01-30,COMT inhibiting methods and compositions,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEVELOPMENT,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID PRICE;;WEINBERGER DANIEL,LIEBER INSTITUTE INC (2016-05-24),https://lens.org/186-771-841-764-568,Granted Patent,yes,6,0,12,12,0,A61K45/06;;A61K31/4725;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P43/00;;C07D471/10;;A61K31/47;;C07D215/36;;A61K31/4709;;C07D401/12;;A61K31/496;;A61K31/5377;;C07D471/04;;C07D401/14;;A61K31/55;;C07D417/12;;A61K31/198;;A61K45/06;;A61K31/4725,A61K31/00;;A61K31/198;;A61K31/47;;A61K31/4709;;A61K31/4725;;A61K31/496;;A61K31/5377;;A61K31/55;;A61K45/06;;C07D215/36;;C07D401/12;;C07D401/14;;C07D417/12;;C07D471/04;;C07D471/10,,18,11,073-142-614-942-038;;156-960-155-177-181;;024-573-559-164-700;;013-686-033-804-234;;074-688-381-260-853;;052-852-123-441-188;;000-505-287-507-099;;028-724-570-628-95X;;067-168-304-275-215;;083-088-149-085-066;;146-696-127-349-975,23247256;;10.1016/j.bioorg.2012.10.003;;10.1080/10426509108036821;;10.2174/22113626130104;;22870804;;10.1007/s12272-012-0602-0;;14361901;;10.4269/ajtmh.1955.4.224;;10.1002/jctb.280550202;;pmc6256987;;20110891;;10.3390/molecules15010288;;10.1016/j.bmc.2014.06.017;;25002230;;10.1021/cm035313i;;10.1135/cccc19932222;;10.1021/cm9503442,"Eweas et al, Design, synthesis, anti-schistosomal activity and molecualr docking of novel 8-hydroxyquinoline-5-sulfonyl 1,4-diazepine derivatives ,Bioorganic Chemistry, 2013, 46, p. 17-25.;;Patwa et al, Fries reaction. Part XIII: Preparation of 5- or 7-arylsulfonyl 8-hydroxyquinoline, Journal of the Institution of Chemists (India), 1976, 48, pt. 3, p. 116-18, abstract (1 page).;;Hafez et al, Synthesis and application of some new 5-sulfonyl-N-heterocyclyl-8-hydroxyquinoline derivatvies as potential drugs, Phosphorus, Sulfur and Silicon and the Related Elements, 1991, 61(3-4), p. 381-9, abstract (2 pages).;;Makhlouf et al , Effect of chelating 8-hydroxyquinoline derivatives on the corrosion of zinc in polybasic acids, Journal of the Electrochemical Society of India, 1986,35(2), p. 89-92, an abstract page (Year: 1986).;;Abdel Hafez et al, Synthesis and biological activity of some new 8-hydroxyquinoline sulfonamide derivatives, Phosphorus, Sulfur and the Related Elements, 1988, 40(3-4), p. 219-225 ,an abstract page (Year: 1988).;;Eweas et al, Synthesis, antischstosomal activity and molecular modeling of two novel 8-hydroxyquinoline derivatives, Anti-Infective Agents, 2013, 11(1), p. 31-40, an abstract page (Year: 2013).;;Kassem et al, Synthesis, antimicrobial , and antiviral activities of some new 5-sulphonamido-8-hydroquinoline derivatives, Archives of PharmacalResearch, 2012, 35(6), p. 955-964. (Year: 2012).;;Tewari et al, 8-hydroxyquinolino-5-(p-tolyl)sulfonamide as a new gravimetric reagent for chromium (III), Science and Culture, 1980, 46(10), p. 357-358, an abstract page. (Year: 1980).;;Thompson et al, 5-chloro-7-diethylaminomethyl-8-quinolinol and of other substituted 8-quinolinols in vitro and in experimental animals, American Journal of Tropical Medicine and hygiene, 1955, 4, p. 224-248. (Year: 1955).;;Abdel Hafez et al , Nitriles in heterocyclic synthesis. Part II. synthesis and application of pyrano[3,2-h]quinoline sulfonamide derivatives, Journal of Chemical Technology and Biotechnology, 1992, 55(2), p. 95-101 ,an abstract page (Year: 1992).;;Kassem et al, Synthesis of some new derivaitves of 8-hydroxyquinoline of possible biological activity, Bulletin of the National Research Centre(Egypt),1997, 22(1), p. 97-106, an abstract page (Year: 1997).;;Musiol et al, Investigating the activity spectrum for ring-substituted 8-hydroxyquinolines, Molecules , 2010, 15, p. 288-304, an abstract page (Year: 2010).;;Lieber Institute for Brain Development, Notification of Transmittal of the International Search Report and the Written Opinion of the International Search Authority, or the Declaration for PCT/US16/15832, 12 pages, dated Apr. 11, 2016.;;Ariyasu et al., “Design and Synthesis of 8-hrydroxyquinoline-based Radioprotective Agents,” Bioorganic & Medicinal Chemistry, vol. 22, No. 15, pp. 3891-3905, 2014.;;Cheng et al., “Solution-processible Small Molecular Organic Light-Emitting Diode Material and Devices based on the Substituted Aluminum Quinolate,” Chem. Mater., vol. 16, No. 15, pp. 2862-2868, 2004.;;Hafez et al., “Synthesis of Some Heterocyclic Sulfones Related to Quinolinol,” Collect. Czech. Chem. Commun., vol. 58, pp. 2222-2226,1993.;;Hopkins et al., “Substituted Aluminum and Zinc Quinolates with Blue-Shifted Absorbance/luminescence Bands: Synthesis and Spectroscopic, Photoluminescence, and Electroluminescence Characterization,” Chemistry of Materials, vol. 8, No. 2, pp. 344-351, 1996.;;Lieber Institute for Brain Development, Supplementary European Search Report for EP 16744242.5, 8 pages, Jan. 8, 2018.",ACTIVE
100,US,A1,US 2016/0222001 A1,166-561-150-598-803,2016-08-04,2016,US 201615011365 A,2016-01-29,US 201615011365 A;;US 201562109956 P,2015-01-30,COMT Inhibiting Methods and Compositions,"The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.",LIEBER INST FOR BRAIN DEV,BARROW JAMES;;ERNST GLEN;;HUANG YIFANG;;BUCHLER INGRID PRICE;;WEINBERGER DANIEL,LIEBER INSTITUTE INC (2016-05-26),https://lens.org/166-561-150-598-803,Patent Application,yes,0,4,4,4,0,A61K31/198;;A61K31/198;;A61P25/00;;A61P25/18;;A61P25/28;;A61P25/30;;C07D417/12;;C07D417/12;;C07D215/26;;C07D215/26;;C07D401/12;;C07D401/12;;C07D405/12;;C07D405/12,C07D417/12;;A61K31/198;;A61K31/47;;C07D215/26;;C07D401/12;;C07D405/12,,0,0,,,,ACTIVE
101,US,A,US 4346923 A,047-500-414-196-792,1982-08-31,1982,US 6951679 A,1979-08-23,US 6951679 A,1979-08-23,Apparatus for joining tubing,"A leak-tight noncontaminative joint connecting a section of titanium, tantalum, zirconium or stainless steel tubing with second section of titanium, tantalum, zirconium or stainless steel tubing of a larger diameter is formed by placing a compressible O-ring, a slidable, nontitanium, nontantalum, nonzirconium or nonstainless steel ferrule and a fixed, nontitanium, nontantalum, nonzirconium or nonstainless steel mechanical stop around the outer surface of the smaller tubing and inserting the smaller tubing into the larger tubing so as to compress the O-ring between the two sections, until the ferrule, which conformably engages the inner surface of the larger tubing, is driven firmly against the mechanical stop. In this arrangement the fluid being transported within the titanium, tantalum, zirconium or stainless steel tubings is unable to pass by the O-ring and thus does not contact either the nontitanium, nontantalum, nonzirconium or nonstainless steel ferrule or stop. A coupling nut for holding the two joined pieces of tubing together is also disclosed.",VAPONICS,SMITH VERITY C;;BAKER ROBERT J;;BARROW JR WYILE W;;DOANE H DANIEL,,https://lens.org/047-500-414-196-792,Granted Patent,yes,9,7,1,1,0,F16L19/103;;F16L19/103,F16L19/10,F2G G22A          G22A;;F2G G28           G22A,0,0,,,,EXPIRED
102,WO,A1,WO 2023/023104 A1,049-703-913-956-664,2023-02-23,2023,US 2022/0040525 W,2022-08-17,US 202163234336 P,2021-08-18,"SYSTEM AND METHOD FOR AUTOMATIC ANALYSIS OF TEXTS IN PSYCHOTHERAPY, COUNSELING, AND OTHER MENTAL HEALTH MANAGEMENT ACTIVITIES","A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts.",MIND MEDICINE INC,KOLAR ADAM;;MAJERNIK MARTIN;;PINHEIRO MIGUEL AMAVEL DOS SANTOS;;KARLIN DANIEL R;;BARROW ROBERT,,https://lens.org/049-703-913-956-664,Patent Application,yes,1,0,5,5,0,G16H50/20;;G16H50/30;;A61B5/7267;;A61B5/165;;A61B5/4803;;A61B5/0077;;G10L15/26;;G06F40/30;;G06F40/279;;G16H50/50;;G16H10/20;;G16H20/70;;A61B5/4803;;A61B5/16;;G16H20/70;;G16H50/20;;G16H15/00,G16H20/70,,0,0,,,,PENDING
103,CA,A1,CA 3229158 A1,127-859-424-686-016,2023-02-23,2023,CA 3229158 A,2022-08-17,US 202163234336 P;;US 2022/0040525 W,2021-08-18,"SYSTEM AND METHOD FOR AUTOMATIC ANALYSIS OF TEXTS IN PSYCHOTHERAPY, COUNSELING, AND OTHER MENTAL HEALTH MANAGEMENT ACTIVITIES","A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts.",MIND MEDICINE INC,KOLAR ADAM;;MAJERNIK MARTIN;;PINHEIRO MIGUEL AMAVEL DOS SANTOS;;KARLIN DANIEL R;;BARROW ROBERT,,https://lens.org/127-859-424-686-016,Patent Application,no,0,0,5,5,0,G16H50/20;;G16H50/30;;A61B5/7267;;A61B5/165;;A61B5/4803;;A61B5/0077;;G10L15/26;;G06F40/30;;G06F40/279;;G16H50/50;;G16H10/20;;G16H20/70;;A61B5/4803;;A61B5/16;;G16H20/70;;G16H50/20;;G16H15/00,G16H20/70,,0,0,,,,PENDING
104,AU,A1,AU 2022/329967 A1,146-225-531-695-465,2024-02-15,2024,AU 2022/329967 A,2022-08-17,US 202163234336 P;;US 2022/0040525 W,2021-08-18,"SYSTEM AND METHOD FOR AUTOMATIC ANALYSIS OF TEXTS IN PSYCHOTHERAPY, COUNSELING, AND OTHER MENTAL HEALTH MANAGEMENT ACTIVITIES","A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts.",MIND MEDICINE INC,KOLAR ADAM;;MAJERNIK MARTIN;;PINHEIRO MIGUEL AMAVEL DOS SANTOS;;KARLIN DANIEL R;;BARROW ROBERT,,https://lens.org/146-225-531-695-465,Patent Application,no,0,0,5,5,0,G16H50/20;;G16H50/30;;A61B5/7267;;A61B5/165;;A61B5/4803;;A61B5/0077;;G10L15/26;;G06F40/30;;G06F40/279;;G16H50/50;;G16H10/20;;G16H20/70;;A61B5/4803;;A61B5/16;;G16H20/70;;G16H50/20;;G16H15/00,G16H20/70,,0,0,,,,PENDING
105,US,A1,US 2023/0053429 A1,151-091-899-533-827,2023-02-23,2023,US 202217889415 A,2022-08-17,US 202217889415 A;;US 202163234336 P,2021-08-18,"SYSTEM AND METHOD FOR AUTOMATIC ANALYSIS OF TEXTS IN PSYCHOTHERAPY, COUNSELING, AND OTHER MENTAL HEALTH MANAGEMENT ACTIVITIES","A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts.",MIND MEDICINE INC,KOLAR ADAM;;MAJERNIK MARTIN;;PINHEIRO MIGUEL AMAVEL DOS SANTOS;;KARLIN DANIEL R;;BARROW ROBERT,MIND MEDICINE INC (2021-08-25),https://lens.org/151-091-899-533-827,Patent Application,yes,4,0,5,5,0,G16H50/20;;G16H50/30;;A61B5/7267;;A61B5/165;;A61B5/4803;;A61B5/0077;;G10L15/26;;G06F40/30;;G06F40/279;;G16H50/50;;G16H10/20;;G16H20/70;;A61B5/4803;;A61B5/16;;G16H20/70;;G16H50/20;;G16H15/00,A61B5/16;;A61B5/00,,0,0,,,,PENDING
106,TW,A,TW 202309928 A,144-296-219-023-395,2023-03-01,2023,TW 111130555 A,2022-08-15,US 202163234336 P,2021-08-18,"System and method for automatic analysis of texts in psychotherapy, counseling, and other mental health management activities","A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts.",MIND MEDICINE INC,KOLAR ADAM;;MAJERNIK MARTIN;;PINHEIRO MIGUEL AMAVEL DOS SANTOS;;KARLIN DANIEL R;;BARROW ROBERT,,https://lens.org/144-296-219-023-395,Patent of Addition,no,0,0,5,5,0,G16H50/20;;G16H50/30;;A61B5/7267;;A61B5/165;;A61B5/4803;;A61B5/0077;;G10L15/26;;G06F40/30;;G06F40/279;;G16H50/50;;G16H10/20;;G16H20/70;;A61B5/4803;;A61B5/16;;G16H20/70;;G16H50/20;;G16H15/00,G16H80/00;;G16H15/00;;G16H50/20,,0,0,,,,PENDING
107,TW,A,TW 201138548 A,169-187-225-619-085,2011-11-01,2011,TW 99135022 A,2010-10-14,US 27891409 P,2009-10-14,Dimmer decoder with improved efficiency for use with LED drivers,"One method includes sampling a subset of pulses in a sense signal (asense) during each of multiple sampling periods, where the sense signal is based on an output of a dimmer (104) and the subset of pulses includes multiple pulses during that sampling period but not one or more initial pulses at a beginning of that sampling period. Another method includes identifying at least one pulse duty cycle for at least one pulse in the sense signal during each of multiple sampling periods and adjusting a filter (423) based on a rate at which the output of the dimmer changes. Yet another method includes sampling at least one pulse in the sense signal and calculating a duty cycle of the at least one pulse, where a holding current is generated for the dimmer (i) during the sampling and (ii) when the pulse duty cycle is less than a specified threshold.",NAT SEMICONDUCTOR CORP,BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;YUEN LAI CHI,,https://lens.org/169-187-225-619-085,Patent of Addition,no,0,1,10,10,0,H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385;;H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385,H05B37/02;;H05B44/00,,0,0,,,,ACTIVE
108,WO,A2,WO 2011/047110 A2,118-772-501-997-814,2011-04-21,2011,US 2010/0052590 W,2010-10-14,US 27891409 P,2009-10-14,DIMMER DECODER WITH IMPROVED EFFICIENCY FOR USE WITH LED DRIVERS,"One method includes sampling a subset of pulses in a sense signal (asense) during each of multiple sampling periods, where the sense signal is based on an output of a dimmer (104) and the subset of pulses includes multiple pulses during that sampling period but not one or more initial pulses at a beginning of that sampling period. Another method includes identifying at least one pulse duty cycle for at least one pulse in the sense signal during each of multiple sampling periods and adjusting a filter (423) based on a rate at which the output of the dimmer changes. Yet another method includes sampling at least one pulse in the sense signal and calculating a duty cycle of the at least one pulse, where a holding current is generated for the dimmer (i) during the sampling and (ii) when the pulse duty cycle is less than a specified threshold.",NAT SEMICONDUCTOR CORP;;BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;YUEN LAI CHI,BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;YUEN LAI CHI,,https://lens.org/118-772-501-997-814,Patent Application,yes,0,0,10,10,0,H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385;;H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385,H05B44/00;;H05B37/02,,0,0,,,,PENDING
109,TW,B,TW I542248 B,029-347-204-576-200,2016-07-11,2016,TW 99135022 A,2010-10-14,US 27891409 P,2009-10-14,Dimmer decoder with improved efficiency for use with led drivers,,NAT SEMICONDUCTOR CORP,BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;YUEN LAI CHI,,https://lens.org/029-347-204-576-200,Granted Patent,no,0,0,10,10,0,H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385;;H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385,H05B44/00,,0,0,,,,ACTIVE
110,US,B2,US 8531138 B2,048-617-982-318-933,2013-09-10,2013,US 90453510 A,2010-10-14,US 90453510 A;;US 27891409 P,2009-10-14,Dimmer decoder with improved efficiency for use with LED drivers,"A method includes receiving a sense signal having multiple pulses, where the sense signal is based on an output of a dimmer. The method also includes, for each of multiple sampling periods, sampling a subset of the pulses in the sense signal during that sampling period. The method further includes generating a holding current for the dimmer during the sampling of the subset of pulses in at least one of the sampling periods. In addition, the method includes, for each of the sampling periods, generating an output value identifying a duty cycle for driving one or more light emitting diodes (LEDs). The subset of pulses in each of the sampling periods includes multiple pulses during that sampling period but not one or more initial pulses at a beginning of that sampling period.",BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;LAI CHI YUEN;;NAT SEMICONDUCTOR CORP,BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;LAI CHI YUEN,NATIONAL SEMICONDUCTOR CORPORATION (2010-11-10),https://lens.org/048-617-982-318-933,Granted Patent,yes,14,0,10,10,0,H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385;;H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385,H05B37/02;;H05B44/00,315/360;;315/250;;315/307,5,0,,,"Notification of Transmittal of The International Search Report and The Written Opinion of the International Searching Authority, or the Declaration dated Jun. 1, 2011 in connection with International Patent Application No. PCT/US2010/052590.;;Matthew Reynolds, ""LM3445 Off-Line TRIAC Dimmer LED Driver Demo Board"", National Semiconductor Corporation, Apr. 14, 2009, 8 pages.;;""LM3445 Off-Line TRIAC Dimmer LED Driver Reference Design"", National Semiconductor Corporation, Feb. 2009, 9 pages.;;""Triac Dimmable Offline LED Driver"", National Semiconductor Corporation, Mar. 23, 2009, 26 pages.;;""SSL2101, SMPS IC for dimmable LED lighting"", NXP, B.V., Aug. 28, 2009, 22 pages.",ACTIVE
111,WO,A3,WO 2011/047110 A3,007-320-088-358-370,2011-07-28,2011,US 2010/0052590 W,2010-10-14,US 27891409 P,2009-10-14,DIMMER DECODER WITH IMPROVED EFFICIENCY FOR USE WITH LED DRIVERS,"One method includes sampling a subset of pulses in a sense signal (asense) during each of multiple sampling periods, where the sense signal is based on an output of a dimmer (104) and the subset of pulses includes multiple pulses during that sampling period but not one or more initial pulses at a beginning of that sampling period. Another method includes identifying at least one pulse duty cycle for at least one pulse in the sense signal during each of multiple sampling periods and adjusting a filter (423) based on a rate at which the output of the dimmer changes. Yet another method includes sampling at least one pulse in the sense signal and calculating a duty cycle of the at least one pulse, where a holding current is generated for the dimmer (i) during the sampling and (ii) when the pulse duty cycle is less than a specified threshold.",NAT SEMICONDUCTOR CORP;;BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;YUEN LAI CHI,BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;YUEN LAI CHI,,https://lens.org/007-320-088-358-370,Search Report,yes,4,0,10,10,0,H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385;;H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385,H05B44/00;;H05B37/02,,0,0,,,,PENDING
112,US,A1,US 2011/0115395 A1,096-517-042-083-401,2011-05-19,2011,US 90453510 A,2010-10-14,US 90453510 A;;US 27891409 P,2009-10-14,DIMMER DECODER WITH IMPROVED EFFICIENCY FOR USE WITH LED DRIVERS,"A method includes receiving a sense signal having multiple pulses, where the sense signal is based on an output of a dimmer. The method also includes, for each of multiple sampling periods, sampling a subset of the pulses in the sense signal during that sampling period. The method further includes generating a holding current for the dimmer during the sampling of the subset of pulses in at least one of the sampling periods. In addition, the method includes, for each of the sampling periods, generating an output value identifying a duty cycle for driving one or more light emitting diodes (LEDs). The subset of pulses in each of the sampling periods includes multiple pulses during that sampling period but not one or more initial pulses at a beginning of that sampling period.",NAT SEMICONDUCTOR CORP,BARROW STEVEN M;;MASSON JAMES H;;HERRINGTON DANIEL R;;NEDERBRAGT IRWIN R;;LAI CHI YUEN,NATIONAL SEMICONDUCTOR CORPORATION (2010-11-10),https://lens.org/096-517-042-083-401,Patent Application,yes,14,36,10,10,0,H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385;;H05B45/10;;Y02B20/30;;H05B45/375;;H05B45/385,H05B41/16;;H05B44/00,315/250,0,0,,,,ACTIVE
113,ES,T3,ES 2284127 T3,001-434-930-292-180,2007-11-01,2007,ES 05104891 T,2005-06-06,GB 0416567 A;;GB 0419306 A,2004-07-24,DISPOSICIONES DE EXPOSICION SUSPENDIDAS.,"An arrangement for hanging printed sheet material for display in which the sheet is printed on at least a front face; has an upper selvedge bounded by an edge of the sheet and at least one score line; said edge is contoured to define one or more tabs; a corresponding number of tab-receiving slots are provided in or adjacent to the selvedge or said score line, and an aperture is provided in the or each tab such that, with the upper selvedge folded over and the or each tab inserted into the or each associated tab-receiving slot to protrude upwardly therefrom. The upper selvedge enhances the rigidity of the sheet and the aperture or apertures in the protruding tab or tabs provide means for use in hanging the sheet.",AUGUSTUS MARTIN LTD,BARROW LASCELLES AUGUSTUS AUGU;;PATEL DAKSHESH SHASHIKANT AUGU;;PATTISON DANIEL AUGUSTUS MARTI;;STOKES GLYN AUGUSTUS MARTIN LI,,https://lens.org/001-434-930-292-180,Granted Patent,no,0,0,8,15,0,G09F1/103,G09F1/10;;G09F17/00,,0,0,,,,ACTIVE
114,EP,A3,EP 1619646 A3,185-948-470-196-833,2006-02-08,2006,EP 05104891 A,2005-06-06,GB 0416567 A;;GB 0419306 A,2004-07-24,Hanging display arrangements,"An arrangement for hanging printed sheet material for display in which the sheet is printed on at least a front face; has an upper selvedge bounded by an edge of the sheet and at least one score line; said edge is contoured to define one or more tabs; a corresponding number of tab-receiving slots are provided in or adjacent to the selvedge or said score line, and an aperture is provided in the or each tab such that, with the upper selvedge folded over and the or each tab inserted into the or each associated tab-receiving slot to protrude upwardly therefrom. The upper selvedge enhances the rigidity of the sheet and the aperture or apertures in the protruding tab or tabs provide means for use in hanging the sheet.
",AUGUSTUS MARTIN LTD,BARROW LASCELLES AUGUSTUS AUGU;;PATEL DAKSHESH SHASHIKANT AUGU;;PATTISON DANIEL AUGUSTUS MARTI;;STOKES GLYN AUGUSTUS MARTIN LI,,https://lens.org/185-948-470-196-833,Search Report,yes,3,0,8,15,0,G09F1/103,G09F1/10;;G09F17/00,,0,0,,,,ACTIVE
115,WO,A1,WO 2003/013526 A1,067-375-263-106-117,2003-02-20,2003,US 0224664 W,2002-08-02,US 31092701 P;;US 34992502 P,2001-08-08,ANTICOAGULANT COMPOUNDS,"Compounds of the invention are useful in inhibiting carboxypeptidase U and associated thrombotic occlusions having the structure (I) and pharmaceutically acceptable salts thereof, wherein t is N or N(R2'), u is C(R3) or N(R2'), and v is C(R2), N or N(R2), provided that, 1) when t is N and u is C(R3), then v is N(R2); 2) when t is N and u is N(R2'), then v is C(R2), and 3) when t is N(R2') and u is C(R3), then v is N or N(R2).",MERCK & CO INC;;BARROW JAMES C;;SELNICK HAROLD G;;NANTERMET PHILIPPE G;;RITTLE KENNETH E;;MCMASTERS DANIEL R;;STAUFFER SHAUN R;;BOLINGER STACEY,BARROW JAMES C;;SELNICK HAROLD G;;NANTERMET PHILIPPE G;;RITTLE KENNETH E;;MCMASTERS DANIEL R;;STAUFFER SHAUN R;;BOLINGER STACEY,,https://lens.org/067-375-263-106-117,Patent Application,yes,1,0,1,1,0,A61K31/4439;;C07D233/64;;C07D401/04;;C07D401/14;;C07D405/14,A61K31/4439;;C07D231/12;;C07D233/54;;C07D401/04;;C07D401/14;;C07D405/14,,0,0,,,,PENDING
